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Cost of Pyelonephritis in Type- 2 Diabetes  
(COPID study) - A cost of illness study 
 
 
 
INTRODUCTION 
 
 
Diabetes Mellitus poses a great economic burden to the family. One of the important 
causes of a hospital admission of the diabetic patient is acute Pyelonephritis. The 
management includes empiric antimicrobial therapy based on local susceptibility 
pattern, isolation of the organism followed by pathogen directed therapy. With the rise 
in the incidence of Extended spectrum beta lactamase producing organisms, the cost 
of care has significantly increased. Besides this diabetes predisposes the patient to 
develop complications of Pyelonephritis which also increase the cost.  
There is a need to quantify this burden in the Indian setting. Besides this, the indirect 
and intangible costs which are often overlooked also contributes significantly to the 
cost of care. 
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HYPOTHESIS 
 
 
Our hypothesis was that Diabetic patients would have a higher cost than non-Diabetic 
patients during their admission with a poorer quality of life.  
 
AIM 
To estimate the cost of Acute Pyelonephritis in patients with Type 2 Diabetes mellitus 
admitted in general medical wards   
 
OBJECTIVES 
1. To estimate the total cost of a single admission for  Acute Pyelonephritis    
2. To estimate the difference in cost of admission for Acute Pyelonephritis between 
Diabetics and Non-Diabetics   
3. To find the difference of cost of admission for Acute Pyelonephritis caused by 
ESBL organisms and non-ESBL organisms   
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LITERATURE REVEIW 
 
 
Global economic burden of Diabetes 
 
Diabetes causes substantial economic burden globally. A recent cost of illness study 
estimated global cost of diabetes with data from 184 countries including low and 
middle income countries. The global cost in 2015 based on the study was around US$ 
1.31 trillion or 1.8-1.9 of global gross domestic product (GDP). (1) The indirect costs 
also contributed significantly to the cost of care (around 34.7%). The labour force 
drop out (48.5%) and mortality (45.5%) contributed to the indirect costs majorly 
followed by absenteeism. In the low income and middle income countries analysis of 
86 cost of illness studies from 2001 to 2014 estimated annual direct costs ranging 
from INT$ 242 to $4129. (2) 
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Table 1 Global Economic burden of Diabetes in 2015. Adapted from Bommer et al(1) 
 
Region Indirect costs Percentage of GDP 
Sub-saharan Africa 19.45 (44%) 1.2% 
East Asia and Pacific 318.89 (38.2%) 1.6% 
Europe and Central 
Asia 
276.31 (30.8%) 1.4% 
Latin America and the 
Caribbean 
129.89 (21.9%) 2.4% 
Middle East and North 
Africa 
41.97 (35.1%) 1.3% 
North America 499.40 (36.3%) 2.6% 
South Asia 25.86 (57.4%) 1.0% 
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Health care in India 
 
Health care in India is primarily from the private medical sector. 70% of the urban and 
63% of rural India gain access to health though the private sector. However only 28.7% 
of the households (urban 28.2%, rural 29%) have any member covered by a health 
scheme or insurance(3). The public sector has national programmes to cover for HIV, 
Tuberculosis and Leprosy. But such a system is not existential for Diabetes and its 
complications. Around 8.0% men and 5.8% women have diabetes in India (3). A report 
by the health care access initiatives by a pharmaceutical company exposed that nearly 
63 million are in debt and a third of them are pushed below the poverty line due to 
health care expenditure(4).  Hence to understand the burden of disease in regards to the 
economy, cost analytical studies are needed.  
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Diabetes in India 
 
Diabetes is a major contributor to morbidity and mortality in both infectious and non-
communicable diseases. The International Diabetes Federation has ranked India only 
next to China with about 69.2 million people (56.2- 133.4 million) with Diabetes in 
2015(5).  The proportional mortality due to Diabetes is 2% based on WHO Non 
communicable diseases country profile (2014) which accounts to 1. 96 million 
deaths(6).  
By the thrifty genotype theory by which the genetic material are adapted to the 
environment, Indians are programmed to a low calorie diet. With the sudden increase 
in lifestyle and diet, the body is unable to tolerate the high calorie intake predisposing 
them to diabetes(7). The process starts even before birth when the insulin resistance 
develops. This happens as the muscle of the foetus becomes resistant to insulin while 
developing in the uterus. Based on the New Delhi birth cohort, it has been noted that 
those who gain weight not necessarily the obese are more predisposed to developing 
Diabetes (8). Hence the Indian genotype need not be obese to develop Diabetes.  
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Cost of Diabetes in India 
 
India is a growing economy. The GDP in 2073.54 billion $US (Rs.1,35,796.13 billion) 
and estimated annual wages are 1203.54 $US (Rs.78,819.83). Diabetes in India a 
growing epidemic. Because of the chronic nature of the illness, the costs incurred lays 
a huge burden. The prevalence of Diabetes Mellitus among the age group 20-79 based 
on the IDF data is 8.7% (7.0-10.6%).  The total cost of Diabetes Mellitus in percent of 
GDP is 1.04 (0.87- 1.25). Of this the direct costs account to 0.46% (0.39- 0.56%). (1) 
Direct costs in percent of total health expenditure is around 9.18 (7.67-11.07) amounting 
to 9.58 million $US (Rs.627.39 million). Direct costs per patient was 138.52 $US 
(Rs.9071.67).  A low income Indian family would roughly spend around 25% of the 
total family income to diabetic care. It has been found that the largest single expenditure 
for Diabetes care in India is inpatient hospital admission (9).  
 
Table 2 Distribution of Indirect costs due to diabetes in India (1) 
Absenteeism Labour force drop out Mortality  Presenteeism 
0.02 (0.02-0.03) 0.11 (0.09-0.13) 0.44 (0.37-0.52) 0.01 (0.01-0.01) 
 
 
Comparing the global data the indirect costs due to mortality seems to contributing 
majorly to the indirect costs.  
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The total annual expenditure for diabetes is around US $227 (10000 INR) in urban areas 
and US $142 (6260 INR) in the rural areas. Low-income groups spend a higher 
proportion of their income on diabetes care (34% in urban low socio economic status 
versus 27% rural low socioeconomic status). The medical costs in a patient with 
diabetes multiple two to fivefold higher than those without diabetes(10). The problem 
is a vicious cycle when the diabetes is uncontrolled because of cost issues leading to 
more complications which further increases the cost. 
Indian studies have shown that the comorbidities and complications in diabetes are more 
in the lower socio economic group. (11). They have also showed that since the lower 
socio economic group sought health care later, they had more complications. There was 
a difference of 7 years in the age of diagnosis between the economic groups. The costs 
subsequently will increase since the diabetes would be uncontrolled and complications 
could have set it. This is a classic example of the link between health and poverty where 
the poor are driven below the poverty line when a major complication occurs. (11). 
It is appropriate to look at the landmark economic studies done in diabetes in India. The 
CODI (Cost of Diabetes in India) was a community based study done to survey the cost 
of Diabetes in India(12). It was preceded by the Bangalore Urban district study (BUD 
study) which is a pilot study. The results showed that 65% of the costs were ambulatory 
care and 35% was due to hospitalisations. Though the therapy amounted 31% the 
specific anti-diabetic drugs was only 17%.  
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Figure 1 Direct costs in Diabetic care (Adapted from Kapur et al)(12) 
 
 
Hospitalisation increases the cost of care. Cardiac complications were the most common 
and the costliest cause of hospitalisation followed by a non-healing wound(12). The 
overall cost of hospitalisation was around $US 200 (Rs.13,098). The hospitalisation for 
a Type 1 diabetic the cost was $US 120 (Rs.7,858.80) when compared to a type 2 
diabetic which was $US 206 (Rs.13,490.94). When there were no complications the 
cost was $US 154 (Rs.10,085.46) however when there were more than 3 complications 
the costs increased to $US 259 (Rs.16,961.91). 
Majority (89%) of the people used their household income to fund the treatment of 
Diabetes. Few others utilised government hospitals which are free. 22% of the elderly 
and 19% of the low socioeconomic group used their savings. When hospitalised he 
percentage of people who spent from their savings increased to 34%. 9-10% obtained 
loans from the employers and only 1 percent had insurance.  
35%, 35%
12%, 12%22%, 22%
17%, 17%
11%, 11%
3%, 3%
Hospitalisation Doctor visit Monitoring and lab Anti-diabetic drugs Other drugs Disposables
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Socioeconomic status and health-care 
 
The socio-economic status of an individual has important implications in health and 
health care. A low socio-economic status curtails access to proper nutrition and health 
care. In fact, a multicohort study and meta-analysis of 1.7 million people has shown 
that low socio-economic status was an independent and modifiable risk factor of 
mortality. (13) This risk is comparable to the risks posed by diabetes, hypertension 
and smoking.  
In India, 73.37% of the households live in the villages. (14) 74.52 % of the people 
have a monthly income of the highest earning household member less than Rs.5000 
(76 $US). 35.73 % of the rural population and 27.2% of the urban population are 
illiterate. The main source of income in 30.10% of the rural population is cultivation 
and 51.18% is casual labour. (14) Hence a significant population belong to the low 
socio-economic group. When assessing the economic burden, it is important to project 
background socio-economic status of the patient in perspective.  
The socio-economic status has been historically divided into high, middle and low. It 
depends on the education, occupation and family income. There are many scales 
available to quantitatively measure the socio-economic status. These have to be 
individualised to each community. In 1976, the Kuppusamy scale was devised which 
is a composite score of education, occupation and monthly family income.(15) The 
family income in this scale is updated every year.  
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Table 3 The modified Kuppusamy scale 
Education Score  
Profession or honours 7 
Graduate or Post-graduate 6 
Intermediate or Post-high school 
diploma 
5 
High school certificate 4 
Middle school certificate 3 
Primary school certificate 2 
Illiterate 1 
Occupation Score  
Professional  10 
Semi-professional 6 
Clerical, Shop-owner, Farmer 5 
Skilled worker 4 
Semi-skilled worker 3 
Unskilled worker 2 
Unemployed 1 
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Family income 
(1976) 
Family Income 
(2014) 
Family Income 
(2017) 
Score  
>2000 >36997 >41430 12 
1000-1999 18498-36996 20715-41429 10 
750-999 13874- 18497 15536-20714 6 
500-749 9249-13873 10357-15535 4 
300-499 5547-9248 6214-10356 3 
101-299 1866-5546 2092-6213 2 
<100 <1865 < 2091 1 
 
 
Socioeconomic Class Score 
Upper class 26-29 
Upper middle class 16-25 
Lower middle class 11-15 
Upper lower class 5-12 
Lower class <5 
Adapted from Oberai et al (15) Tulika singh et al (16) 
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There is also disparity in health care between the socio-economic groups. It varies 
among different countries. (17)  In each country there are unique challenges to bridge 
the gap between the socio-economic groups in regards to health care. In India, with 
the surge of the non-communicable diseases even in the villages and the shift of the 
health care from the public sector to the private sector, many people in the low 
socioeconomic group are pushed below poverty line.  
 
 
PYELONEPHRITIS 
 
 Pyelonephritis is the infection of the upper urinary tract involving the kidneys, upper 
ureter, tissue surrounding the retroperitoneal space or perinephric space with clinical 
features of high grade fever with flank pain and laboratory evidence of pyuria with urine 
and/or blood growing the uro-pathogenic organism (18).  Fever can be absent during 
the initial stage of the illness. Flank pain and renal angle tenderness is almost always 
present and its absence suggests an alternate diagnosis. A positive urinalysis confirms 
a urinary tract infection. Urine culture and blood culture guides antibiotic therapy in 
view of the high rates of community acquired resistant uropathogens. In view of the 
frequency and severity of the disease, accurate diagnosis, decision on antimicrobial 
therapy based on local susceptibility data and expert guidelines is paramount in the 
appropriate management.   
 
 
 
P a g e 14 | 125 
 
 
 
Epidemiology 
 
Urinary tract infections are more common in women. The overall estimated incidence 
rate is 18 per 1000 per year. The majority are community acquired (57.4%), 35.6% are 
hospital acquired and 7% are nosocomial. An estimated 1 in 3 women will have a 
minimum of 1 UTI diagnosed by a physician by the age of 24 and 40-50% will have at 
least 1 Urinary tract infection during their lifetime. Pyelonephritis accounts to 15-20% 
of patients with community acquired bacteraemia and sepsis and 35% in a hospital 
setting(19).  A population based analysis of 3236 cases of pyelonephritis showed annual 
rates of 12-13 outpatient cases per 10,000 population and 3-4 inpatient cases per 10,000 
population among women and 2-3 outpatient cases per 10,000 population and 1-2 
inpatient cases per 10,000 population among men (20).  
Diabetic patients have a 2-4 fold increase in bacteriuria compared to non-diabetic 
patients increasing the chances of an ascending infection (21). It has been shown that 
women with diabetes are 6-24 times more likely to have hospitalisation for 
pyelonephritis and males with diabetes are 3-17 times more likely than non-diabetic 
males (22). 
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Aetiology of pyelonephritis 
 
The uropathogens are predominantly gram negative bacteriae. It is well established that 
Escherichia coli is the most common organism causing pyelonephritis. The pathogens 
differ based on age, presence of diabetes, structural abnormalities, spinal cord injury or 
indwelling catheters. However in all sub categories, Escherichia coli still is the most 
common organism. It is followed by Klebsiella pneumoniae, Staphylococcus 
saprophyticus, Enterococcus faecalis, group B Streptococcus (GBS),Proteus mirabilis, 
Pseudomonas aeroginosa, Staphylococcus aureus and candida species in the order of 
prevelance (23).  Less virulent organisms that rarely cause infection in a normal intact 
urinary tract can cause serious illness otherwise(24). There has been an increase in 
Candida species, Enterococcus species as causative organisms (25). In Diabetic patients 
E-coli is again the most common cause (56.1%) (26). Klebsiella and Group-B 
streptococci have been found to be 2-3 times more common (27). 
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Figure 2 Epidemiology of Urinary tract infections in Uncomplicated urinary tract 
infections. Adapted from Flores-Mirales et al (23) 
 
 
Figure 3 Epidemiology of Urinary tract infections in complicated urinary tract 
infections. Adapted from Flores-Mirales et al (23) 
 
 
75%
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The urinary tract is sterile except for the distal third which contains commensal flora. 
This is protective to ascending infections. Individual susceptibility to urinary tract 
infections depends on genetic, biologic and behavioural factors (Table 1)(28). Each 
species has unique mechanisms that aid in colonisation and invasion which are 
determined by specific bacterial adhesive characteristics, the receptor repertoire on the 
epithelial surface and the surrounding fluids. An important step in the pathogenesis 
involves the colonisation of the urothelium with E-coli. More than 75% of the infections 
are due to progression of this ascending infection. The bacteria can directly invade the 
renal parenchyma from medulla to cortex. The local vascular channels in the kidney 
facilitate the spread/ transport of infection. This leads to development of abscesses 
within the renal parenchyma that can further rupture into the peri-nephric space. This 
space contains peri-nephric fat and the adrenal glands which are in turn surrounded by 
Gerota’s fascia. When the abscess ruptures into this fascia it can track down anteriorly 
through the psoas/ transversalis fascia, superiorly into the sub-diaphragmatic space and 
inferiorly into the pelvis. Presence of urolithiasis is an important predisposing factor for 
development of Pyelonephritis. 
Risk factors for development of recurrent urinary tract infection in young women 
include recent (<1 month) intercourse, spermicide use (12 months), new sexual 
partner,age of first urinary tract infection (≤ 15 years) and urinary tract infection in the 
mother. When an antibiotic is used for a urinary tract infection, there is collateral 
damage resulting in alteration of the commensals in the vagina increasing the risk of 
colonisation by multi drug resistant pathogens. (29) 
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 Colonisation of the kidneys 
Host tissue damage by bacterial 
toxins 
BACTEREMIA 
Contamination of the periurethral area with a uropathogen 
from the gut 
Colonisation of the urethra and migration to the bladder 
Colonisation and 
invasion of the 
bladder (Mediated by 
pili and adhesins) 
Inflammatory 
response in the 
bladder and 
fibrinogen 
accumulation in 
the catheter 
Bacterial multiplication and immune system subversion 
Neutrophil infiltration 
Biofilm formation 
Epithelial damage by bacterial toxins and proteases  
Ascension to the kidneys 
Figure 4 Pathogenesis of urinary tract infections 
P a g e 19 | 125 
 
 
 
Virulence factors associated with Pyelonephritis 
 
 
Uropathogenic virulence factors are less frequently found in the commensal strains of 
fecal E-coli but seen in uropathogenic E-coli. P fimbriae are implicated in the 
pathogenesis because they mediate Gal-Gal- specific bacterial adherence to epithelial 
cells in the urinary tract. This permits bacterial colonization and stimulates 
inflammation. In patients who are immunocompromised the requirement for p fimbriae 
in initiating infection is reduced. Type-1 fimbriae is seen in uropathogenic and 
commensal E-coli. It is essential for colonisation, invasion and persistence. The 
adherence of E-coli with type-1 fimbriae to host cells in the urinary tract may promote 
the development of cystitis. The serological diversity of P fimbriae and the limited 
impact of anti-fimbrial antibodies complicate efforts to develop anti-p fimbrial vaccines 
(30). Bacterial internalisation is mediated by type 1 pilus adhesin, FimH. It also helps 
in invasion through interaction with α3ß3 integrin.  
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Table 4 Virulence factors used by main uropathogens. Adapted from Flores-Mirales et 
al  (23) 
Pathogens 
Virulence factors 
Adherence Toxin 
Immune 
evasion  
Iron 
acquisition 
Other 
UPEC 
F1C pili 
P pili 
S pili 
Type 1 pili 
Dr adhesins 
 
HlyA 
CNF-11 
HlyA 
Capsular 
antigens 
Yersiniabactin 
CNF-1 
 
Antige
n43 
Flagell
a 
Klebsiella 
pneumonia 
Type 1 pili 
Type 3 pili 
 Capsule 
Enterobactin 
Aerobactin 
 
Proteus 
mirabilis 
NAFs 
PMFs 
AipAadhesins 
Taap 
adhesion 
 
Haemoly
sis (HlyA 
and 
HpmA) 
Pta 
ZapA 
Capsule 
Yersiniabactin 
Proteobactin 
 
Urease 
Flagell
a 
Pseudomona
s aeroginosa 
Extracellular 
DNA 
Exopolysacch
arides 
(alginate, 
PEL, PSL) 
- 
Capsule  
Elastase 
ExoS 
Phospholipase 
Rhamnolipids 
Pyochelin 
Pyoverdin 
 
Quoru
m 
sensing 
Staphylococc
us 
saprophyticu
s 
Aas adhesion 
Sdrl adhesin 
Uaf adhesin 
Aas - - Urease 
Enterococcus 
faecalis 
Ebp pili 
Ace adhesin 
Esp adhesin 
- Epa - 
Sortage 
A 
Sig V 
Msr A 
and 
MsrB 
Enterococcus 
faecium 
Ebp pili 
Esp Adhesin 
- - - - 
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E-coli uses iron for synthesising DNA , electron transport and metabolising peroxides. 
In infection, as a part of self-defence the host limits the amount of iron to the 
uropathogenic E-coli. However, the E-coli have developed iron chelating mechanisms 
to combat this. Among them, the hydroxamatesiderophoreaerobactin is the most 
effective. It promotes growth of the bacteria even in limiting iron concentrations (31). 
Hemolysin is the cytolytic protein toxin secreted by uropathogenic E-coli. The most 
common one being α-hemolysin(32). It is seen with the severe forms of infections. It 
includes the release of iron from erythrocytes by lysis, disruption of phagocyte function 
and direct toxicity to host tissues.  
Capsular polysaccharides are linear polymers of repeating carbohydrate units that 
include a prominent amino acid or lipid component. They coat the cell and interfere 
with O-antigen detection. The uropathogenic E-coli have group-II capsular 
Polysaccharides. They aggregate spontaneously because of a phosphatidic acid group. 
Among them, in particular the K1 capsule contribute to virulence by shielding the 
bacteria from phagocytosis and blocks the complement activating pathway (33). 
Limited number of capsular types account for most of the uropathogenic E-coli.   
Colonisation of the renal parenchyma is by the expression of pyelonephritis associated 
pili (P). It binds to globoside containing glycolipids in the renal tissue. PapG, the P pilus 
adhesin interacts with TLR4 reducing the expression of polymeric immunoglobulin 
receptor (PIGR) causing impaired IgA transport across the epithelium. This prevents 
opsonisation and clearance. (34) 
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 Three new candidate genes have been reported to be putative uropathogenic virulence 
genes- usp, iha and iroNE.coli . The ‘usp gene’ is a homologue of the Vibrio choleraezot 
(zonulaoccludens toxin) gene found in uropathogenic E-coli using a DNA probe. In a 
study done in Japan, usp gene was observed in 24% of 50 stool samples with E. coli 
from healthy individuals, 80% of 195 cystitis isolates, and 93% of 76 pyelonephritis 
isolates (35). ‘iha gene’ was originally isolated from the E-coli O157:H7 strain as a part 
of tellurite resistance associated with PAI (Pathogenicity associated island) and is 
similar to the V. cholerae iron-regulated gene A (36). In a study done among 67 isolates 
of E-coli causing urosepsis, the prevalence of iha was found to be 55% (37). 
iroNE.coliwas originally identified in UPEC strain CP9. It is 77% homologous to a 
catecholesiderophore receptor gene observed in Salmonella enterica.  It occurred in 
57% of 14 faecal isolates without the known virulence genes pap, hly, or cnf1. It was 
also seen in 95% of 20 first-UTI isolates, and in 93% of 15 recurrent-UTI isolates. (38) 
Of these genes, iroNE. coli has been found to be strongly associated with UTI 
pathogenesis and usp plays a role in pyelonephritis and colonization of the peri-urethral 
area. The association of usp and iha are weaker in comparison to iroNE. coli(39) 
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Immune response by the body to uropathogenic organism 
 
As the uropathogen invades the bladder epithelial cells, Toll like receptor- 4 (TLR-4) 
recognises the organism and increases the cyclic AMP (cAMP) levels intracellularly. 
This leads to exocytosis of the pathogen and expulsion of the pathogen through the 
urine. If this step is overcome by the pathogen, they undergo autophagy into the 
lysosomes. The pathogens cause the lysosomes lose their degradative capacity. This is 
sensed by the lysosomal transient receptor potential mucolipin 3 channel (TRPML3). 
This causes lysosomal exocytosis leading to expulsion of the pathogen. Besides this the 
bladder epithelial cells also secrete cathelicidin and ß- defensin-1 which are anti-
microbial peptides. They also secrete anti-microbial proteins like pentraxin 3 (PTX 3) 
and chemokines like CCR5 and CXCL-1. The pathogens also cause caspase-3 and 
caspase- 8 mediated apoptosis of the infected bladder epithelial cells. Apart from these, 
the mast cells, natural killer (NK) cells and macrophages secrete chemokines which 
attract neutrophils and other cells of the innate immunity to clear the pathogen. (40) 
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Biofilm formation 
 
 
The pathogens evade the innate immunity by the invasion of the bladder epithelial cells. 
There is replication inside the epithelial cells which serve as bacterial reservoirs. Each 
reservoir has 4-10 non replicating bacteria which can remain latent for months.  This 
can go on for several months before the development of significant bacteruria. These 
appear as numerous protrusion on the surface of urinary bladder termed as pods. On 
examining under scanning electron microscope, the luminal surface of the pods are 
smooth compared to the ruffled surface of the normal bladder epithelium. The pods 
visualised under the transmission electron microscopy (TEM) show bacteria embedded 
in a fibrous matrix in the cytoplasm. There is a halo around the bacteriae separating 
from the cell contents and each other. The matrix and the fibres expressed by the 
bacteria are intertwined providing a scaffold of support to the pathogen. This is the 
biofilm formed by uropathogenic organisms inside the bladder epithelial cells. This 
confers resistance to the organisms to antibiotics and host defences. (41) 
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Pyelonephritis in Diabetics 
 
 
Diabetes causes predisposition to infections by a variety of mechanisms. It results in 
abnormalities in the immunological defence mechanisms like impaired migration, 
intracellular killing, chemotaxis and phagocytosis in leucocytes(42). The humoral 
activity appears to be normal as evidenced by normal response to vaccines. In regards 
to increased cause of urinary tract infections, it can lead to autonomic neuropathy  
causing diabetic cystopathy. This is leads to detrusor areflexia when there is damage to 
the efferent parasympathetic fibres. This causes incomplete bladder voiding, increased 
post-voidal residue, decreased peak urinary flow rate, bladder overdistention, and 
urinary retention(43). This may lead to proliferation of bacteria in the post residual 
collection of urine leading to increase incidence of urinary tract infectios. Glucosuria 
also leads to serve as a culture medium for uropathogens.  
Further, recurrence rates are 25-42% in Diabetic patients which are significantly higher 
than patients without Diabetes. Incidence of Emphysematous Pyelonephritis is higher 
in patients with Diabetes. This is attributed to high levels of glucose, presence of gas 
forming organisms, impaired vascular blood supple, reduced host immunity, and 
presence of obstruction in the urinary tract favouring anaerobic metabolism. Gram 
negative facultative anaerobic organisms like Escherichia Coli are responsible for 
fermenting glucose and lactate producing gas. Carbon dioxide and hydrogen have been 
found to be the principal constituents. Gas may extend beyond the site of inflammation 
to the sub-capsular, perinephric and pararenal spaces. In some cases, gas was found to 
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be extending into the scrotal sac and spermatic cord. Pathological examination of the 
kidney reveals features of abscess formation, foci of micro- and macro-infarctions, 
vascular thrombosis, numerous gas-filled spaces and areas of necrosis surrounded by 
acute and chronic inflammatory cells implying septic infarction 
Further, Diabetes predisposes to complications like Emphysematous cystitis, 
xanthogranulomatous pyelonephritis, intrarenal abscess, acute focal bacterial nephritis, 
acute multifocal bacterial nephritis, renal cortical abscess, renal cortico-medullary 
abscess, prostatic abscesses, perinephric abscess and renal papillary necrosis.  
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Imaging in Pyelonephritis 
 
Imaging is not necessary to diagnose simple pyelonephritis. As recommended by the 
ACR appropriateness criteria, imaging is required only in 5% of the patients who do not 
demonstrate clinical improvement within 72 hours. (44) Imaging should also be used in 
patients who have increased predilection for disease progression, diabetic, pregnant, 
elderly, immunocompromised, have history of urolithiasis or structural abnormalities.  
The purpose of imaging is to rule out an obstructing calculi, complications like 
formation of an abscess and identify rare causes of renal structural abnormalities. (45) 
The recommended CT protocol for complicated urinary tract infection is a non-contrast 
examination (to assess for stone disease) followed by an enhanced phase at 90 to 120 
seconds when there is uniform nephrographic phase enhancement of the renal 
parenchyma.  CT findings of pyelonephritis include a persistent and/or striated 
nephrogram, thickening and mucosal enhancement of the urothelium, renal 
enlargement, and inflammatory changes in Gerota fascia and/or the renal sinus.(46) 
Perinephric collections can also be visualised which may require drainage to rule out an 
abscess. 
 Variant forms of Pyelonephritis include (47) 
1. Hemorrhagic bacterial Nephritis 
2. Focal Pyelonephritis 
3. Hematogenous seeding 
4. Emphysematous Pyelonephritis 
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Ultrasound findings are usually normal in the setting of pyelonephritis. It is useful only 
to exclude obstruction as a cause of Pyelonephritis. Nonspecific findings of 
pyelonephritis 
on ultrasound include focal hypoechoic region with decreased vascular flow, renal 
enlargement, and loss of the sinus fat and/or cortico-medullary differentiation.(47) 
Ultrasound is 90% sensitive and 97% specific for pyonephrosis and a dilated collecting 
system can be visualised. (48) About 75% of renal abscesses occur in diabetic patients 
and can have insidious onset because of lack of flank pain due to diabetic neuropathy. 
Emphysematous Pyelonephritis or pyelitis are seen primarily in diabetic patients. CT is 
the imaging modality of choice. It demonstrates gas in the renal parenchyma, 
asymmetric renal enhancement with delayed contrast excretion and focal areas of 
necrosis and abscesses(49).  
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Extended spectrum beta lactamases 
 
The major antibiotics used against gram negative organisms are beta lactam antibiotics. 
The bacteria to defend against the beta lactams produce beta lactamases. These enzymes 
cleave the beta lactam ring inactivating the antibiotic. The initial Beta lactamases were 
found in staphylococcus aureus as the beta lactams were introduced in the market. Then 
they were also found in organisms (Neisseria gonorrhoea and Haemophilus influenzae) 
that were not known to harbour the enzyme. As the newer antibiotics like 
Cephalosporins, carbapenems and monobactams were introduced into the market, the 
bacteriae adapted by producing a variety of new beta lactamases.  This usually takes 2-
3 years once an antibiotic is introduced. The resistance genes spread by integrons and 
plasmids between the same species and even cross-species. (50) 
 The beta lactamases are of two types 
1. Metalloenzymes 
2. Enzymes with serine residues at the active site 
They can be classified based on the primary structure into 4 molecular classes (A-D) or 
based on the substrate spectrum and the way they respond to inhibitors into functional 
groups.  
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Phylogeny based on Structure of the serine beta lactamases 
 
The Serine beta lactamases use an active serine site to cleave the beta lactam ring. Based 
on the sequence they have been classified into  
1. Class A ß Lactamases 
2. Class C ß Lactamases 
3. Class D ß Lactamases 
Hall and barlow constructed a phylogenetic tree of the above based on the alignment 
of proteins and their structure. It showed that the serine proteases are related to the 
DD peptidases. It also showed the order of descent not the branch length. It describes 
the Class C evolving earlier than Class A and D from a common ancestor. (51) 
 
Figure 5 Phylogenetic Tree of the Serine Proteases 
 
 
The Class B ß Lactamases are metalloenzymes. Though the class B andC have a 
broader spectrum of activity, they are usually confined to a few organisms.  
DD- peptidase 
Class A ßlactamases 
Class D ßlactamases 
Class C ßlactamases 
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Types of Extended Spectrum Beta Lactamases 
 
TEM Type Extended Spectrum Beta lactamases (Class A) 
 
These are created by amino acid substitutions in the TEM-1 beta lactamases. The ones 
with extended spectrum activity have changes in the active site of the enzyme(52). This 
confers action on the oxyimino Beta lactams. The opening of the active site confers 
susceptibility to the beta lactamase inhibitors like clavulinic acid. Extended spectrum 
beta lactamases are usually not compatible with inhibitor resistance.  Around 220 TEM 
enzymes have been described of which TEM 10, TEM 12 and TEM-26 are common.  
SHV Type Extended spectrum Beta lactamases (Class A) 
 
The SHV-1 Type is similar to the TEM-1 sharing around 68% of the amino acids(53). 
They too have a few amino acid substitution around the active site making their activity 
against beta lactamases extended spectrum. 190 varieties have been described among 
which SHV-2, SHV-5, SHV-7 and SHF-12 are the commonest. Not all of the them are 
ESBL. Few of them are active only against penicillins and narrow spectrum 
cephalosporins.  
CTX- M Type Extended Spectrum Beta Lactamases (Class A) 
 
This group has greater activity against Cefotaxime than other Oxyimino beta lactam 
substrates. However few of them hydrolyse Ceftazidime more efficiently. They acquire 
the beta lactamase gene by plasmid mediated transfer from kluyvera species which are 
commensals. Around 160 enzymes are known currently.They are the most common 
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Extended spectrum beta lactamases worldwide. The spread of this group is not because 
they cleave the beta lactams better but rather efficient spread by replicons. (54) 
OXA- Type Extended Spectrum Beta lactamases (Class D) 
 
They are plasmid mediated. They can hydrolyse oxacillin and related anti-
staphylococcal penicillins. They are relatively resistant to inhibition by Clavulinic acid. 
Few of them have amino acid substitutions which confer extended spectrum activity.  
Carbapenemases 
These group of enzymes are active against oxyimino beta lactams, cephamycins and 
carbapenems. Plasmid mediated IMP-type carbapenemases have been observed in 
Acinetobacter and Pseudomonas. The Klebsiella pneumonia carbapenemase is the most 
important enzyme in class A. It is also plasmid mediated. Though it is seen 
predominantly in Klebsiella, there is cross transmission to Escherichia coli, 
Pseudomonas, serratia and Enterobacter species.   
The class B enzymes include IMP, VIM and NDM. The New Delhi metallo-beta 
lactamase (NDM) was first described in an Indian origin man who had travelled to New 
Delhi (55). In our institute we had tested 42 isolates of Escherichia coli and 134 isolates 
of Klebsiella pneumonia from blood culture during 2013-2015 and we screened for 
carbapenemase production by the carba NP test. Among them 95% (n= 167) of them 
had positive test. The isolates were screened specifically for the specific genes which is 
tabulated below. 
P a g e 33 | 125 
 
Table 5 Distribution of carbapenemase resistant genes from organisms isolated from 
2013-2015 in our institute (Adapted from sharma et al) (51) 
    
Carbapenemase resistant 
genes 
E. coli (n=42) 
n(%) 
K. pneumonia 
(n=134) n(%) 
Total N (%) 
NDM 20 (48) 36 (27) 56 (32) 
OXA- 48 like 8 (19) 48 (36) 56 (32) 
VIM 0 2 (1) 2 (1) 
NDM + VIM 7 (17) 2 (1) 5 (9) 
NDM + OXA-48 like 2(5) 20 (15) 13 (13) 
VIM + OXA-48 like 0 (0) 14 (10) 8(14) 
NDM + VIM + OXA-48 0 (0) 14 (10) 8 (14) 
All negatives * 5 (12) 6 (4) 11 6) 
*All negatives- negative for IMP, NDM, VIM, OXA-48 like and KPC 
 
These organisms are usually susceptible to aminoglycosides. Hence Amikacin can be 
a reasonable option. (56) 
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Others 
 
Other Class A Extended spectrum Beta lactamases in Enterobacteriaceae include 
VEB-1 and VEB-2, GES-1, GES-2 and IBC-2. PER-1 is described in the 
Acinetobacter species. Other rare ones include BES-1, IBC-1 SFO-1, TLA-1 
 
Table 6  Selected Beta lactamases (Adapted from George et al) 
Molecular 
class 
ß- lactamase Examples Substrates Inhibition 
by clavulinic 
acid 
A  Broad 
Spectrum 
TEM-1, 
TEM-2, 
SHV-1  
Benzylpenicillin, 
Aminopenicillins, 
Carboxypenicillins, 
Ureidopenicillin,, 
Narrow-spectrum 
cephalosporins 
 
 +++ 
Extended 
spectrum 
TEM family 
and SHV 
family 
Substrates of broad 
spectrum group 
and oxyimino 
cephalosporins and 
monobactams 
 ++++ 
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Others Same as TEM and 
SHV family 
++++ 
CTX-M 
family 
Substrates as the 
expanded group 
plus cefepime for 
few enzymes 
 ++++ 
Carbapenemase  KPC-1, 
KPC-2, 
KPC-3 
Substrates of the 
expanded group 
plus Cephamycins 
and carbapenems  
 +++ 
B  Carbapenemase IMP family, 
VIM family, 
GIM-1, 
SPM-1 
Substrates of the 
expanded group 
plus Cephamycins 
and carbapenems 
0 
C  AmpC 
ACC-1, 
ACT-1, 
CFE-1, 
CMY family, 
DHA-1, 
DHA-2, 
FOX family, 
Substrates of 
expanded-spectrum 
group plus 
cephamycins 
0 
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LAT family, 
MIR-1, 
MOX-1,  
MOX-2 
D  Broad 
Spectrum 
OXA family 
Substrates of the 
broad-spectrum 
group plus 
cloxacillin, 
methicillin,and 
oxacillin 
+ 
Carbapenemase 
OXA-23, 
OXA-24, 
OXA- 
25, OXA-26, 
OXA-27, 
OXA-40,  
OXA-48 
Substrates of the 
expanded group 
plus Cephamycins 
and carbapenems 
+ 
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Treatment of Pyelonephritis 
 
Urinary tract infections are usually caused by Enterobacteriaceae which are gram 
negative organisms and rarely few gram positive organisms like Enterococcus, 
Staphylococcus saprophyticus as described earlier. Since resistance pattern of 
Enterobacteriaceae varies depending on the region, local antimicrobial susceptibility 
patterns are important in treatment.  
Table 7 Pattern of resistance among uropathogens in India 
Place Population       ESBL (%) Quinolones 
Resistance 
(%) 
Reference 
   
Vadodara Adults and 
children 
58.7 - Raval et al(57) 
Aligarh Adults and 
children 
85 69 Akram et al(58) 
Chandigarh Outpatients 21.4 70 Datta et al (59) 
Chennai Outpatients/ 
Inpatients 
70 - Bashini et al (60) 
Dehradun Outpatients 32.08 53.91 Biswas et al (61) 
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Delhi Outpatient 
females 
26.9 64.2 Kothari et al 
(62) 
Lucknow Outpatient 
females 
95.66 (4/46) 60.87 Shaifali et al 
(63) 
Delhi Children 45.1% 76 Kaur et al (64) 
Puducherry Inpatients - 74.2 Niranjan et al 
(65) 
Tirunelveli Adults and 
Children 
73.31 77.43 Nalini et al (66) 
 
Since our institution is a tertiary care referral centre we have noted 21% of the blood 
stream isolates of Escherichia coli (n=725) and 41% of Klebsiella pneumonia (N= 349) 
to be susceptible to Cefpodoxime/ Ceftazidime which is a surrogate marker of extended 
beta lactamase production. The rates of Ciprofloxacin susceptibilty is 30% for 
Escherichia coli and 48% for Klebsiella pneumonia. 92% of the Escherichia coli 
isolated in the blood stream was susceptible to Meropenem.  
Since the rates of Extended spectrum beta lactamase producing organisms are high, 
Carbapenems are the preferred choice of antibiotic in a complicated urinary tract 
infection. This also meant that the cost of treatment would be higher as the carbapenems 
cost more.  
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Cost of Pyelonephritis 
 
Direct medical costs in Pyelonephritis would consist of cost of Antibiotics, Imaging, 
invasive procedures, laboratory investigations and hospital stay. Among these the most 
important factor is the duration of hospital stay(67). The patients with Extended 
spectrum beta lactamse producing organisms would require costlier drugs, with prior 
inappropriate therapy before presentation. Hence the duration of therapy may also 
increase. Diabetic patients with complications like emphysematous pyelonephritis and 
renal abscess would require further imaging like a computed tomography, invasive 
procedures like ultrasound guided aspiration or a percutaneous nephrostomy. Patients 
with advanced infections can present with renal failure requiring haemodialysis.  
Table 8 Components of cost of illness 
Direct Costs Indirect Costs Intangible costs  
Professional fees 
Investigations 
 Invasive 
 Non-invasive 
Treatment 
 Drugs 
Food  
Accommodation 
Travel 
 
Loss of wages 
Loss of wages of care 
giver 
Pain 
Anxiety 
Loss of enjoyment 
Depression 
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Apart from the direct medical costs, the direct non-medical costs, indirect costs and 
intangible costs also should be taken into consideration while evaluating the cost of 
hospitalisation. Direct non-medical costs include transportation to and from the 
hospital, cost of food and accommodation for the patient and the relatives.   The indirect 
costs include productivity loss such as loss of wages and labour force. Intangible loss 
which could not be quantified include fear, anxiety and depression which may affect 
the long term control of Diabetes. 
QUALITY OF LIFE 
 
Health as defined by the WHO is a state of complete physical, mental and social 
wellbeing not just the absence of disease. (68) However health policies are not targeted 
towards the psychological and social aspects because it is often not measured. Often the 
physician overlooks these aspects as the physical body is being treated. Hence beyond 
the usual indicators of health like morbidity and mortality, the impact of the disease in 
the emotional, social life and the surrounding environment should also be considered. 
There are many tools which have been developed to measure these domains. One such 
tool was developed by the World Health Organization.(69) An abbreviated version was 
later released which has 26 subsets and 4 domains. Each domain has a ‘raw score’ which 
is later converted into a ‘transformed score’ on a scale of 0-100 to enable comparison 
between domains. 
Transformed scale= [(Actual possible score-lowest possible score) /Possible raw score 
range] x 100 
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Quality 
of life 
Pain 
Energy 
Medication 
Work  
Sleep 
Mobility 
Activities  
Positive Feelings
Cognition
Self esteem
Body image
Negative feelings
Spirituality
Personal relations
Social support
Sex 
Safety and security 
Home environment 
Finance 
Health/social care 
Information 
Leisure 
Physical environment 
Transport 
Social 
relationships 
Environment 
Psychological  
Physical 
Figure 1The domains in the WHOQOL BREF 
P a g e 42 | 125 
 
The WHOQOL- BREF has been validated and has been tested in two centers in India, 
New Delhi (N= 1456) and Chennai (N= 420).(70) The domain scores adjusted by age 
and sex in the centers has been described below. 
 
Table 1WHOQOL BREF domain scores adjusted by age and sex 
 Physical domain 
Psychological 
domain 
Social Domain 
Environment 
domain 
 Mean SD Mean SD Mean SD Mean SD 
Total 16.2 2.9 15.0 2.8 14.3 3.2 13.5 2.6 
Chennai 14.8 2.3 15.4 2.2 14.8 2.9 14.8 2.5 
Delhi 15.9 2.9 14.2 2.7 13.9 3.7 12.1 2.8 
Adapted from Skevington et al (70) 
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Justification of the study 
 
Our hypothesis was that the cost of Pyelonephritis in Diabetics would be significantly 
higher than those without diabetes.  At present there is a lacunae in literature of the cost 
of illness study of pyelonephritis in Diabetes in India. The direct non-medical costs and 
indirect costs are often overlooked and it bears a huge burden in a developing country 
like India where there are daily wage labourers. We hence studied the cost of illness of 
a single occurrence of Pyelonephritis requiring hospitalisation among diabetics and 
non- diabetics. We have planned to look at the direct medical and non-medical costs, 
indirect costs and intangible loss. We also compared the costs of Pyelonephritis due to 
ESBL organisms versus the non- ESBL organisms. We wanted to observe the factors 
influencing the direct medical, non-medical and indirect costs and if by any means that 
could be reduced or altered to reduce the economic burden of the disease. 
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METHODS 
 
Ethical Approval 
 
This study was conducted after obtaining permission from the Institutional review board 
(IRB Number 9912 dated 05.02.2016 Appendix number 1) prior to commencement of 
the study.  
STUDY DESIGN 
 
Setting 
 
The COPID study (Cost of Pyelonephritis in Type-2 Diabetes) is a prospective 
observational economic study. This was conducted among patients admitted in the 
general medical wards in Christian Medical College, Vellore (CMC). Our hospital is a 
tertiary care hospital primarily catering to middle and low income group patients from 
all over India; predominantly Tamilnadu, Andhra-Pradesh, Karnataka and the North-
Eastern states. Participants were recruited between March 2016 and July 2017. The data 
was collected directly by the principle investigator.  
Participants 
The patients included in the study were those admitted within the general medical 
ward with a clinical and laboratory confirmed diagnosis of Upper Urinary tract 
infection (Pyelonephritis). Participants were eligible if they were above 18 years 
with symptoms of fever, lower urinary tract symptoms, renal angle tenderness, 
laboratory evidence of pyuria, and urine culture and/or blood culture growing an 
Uro-pathogenic organism. We excluded Patients who had previous urological 
procedures, nosocomial or catheter associated infections and those who refused 
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consent. As we were interested in costs we included participants from Southern 
states as costs such as indirect costs vary in large amount across India.  
Procedure 
Once patients were identified, they were given the Information sheet, following 
which written informed consent was obtained (Copy of Information sheet in 
Appendix number 2). All study data were collected by the principle investigator on 
a specially designed Clinical Research form (CRF) (Copy of the CRF in Appendix 
number 3). The participants of the study were interviewed regarding risk factors for 
urinary tract infections, medical co-morbidities including diabetes mellitus, 
systemic hypertension, chronic kidney disease and heart failure. Their urinalysis 
including nitrites and leucocyte esterase were noted. Blood culture and urine culture 
data including presence of extended spectrum beta lactamase (ESBL) and 
Carbapenem resistant organisms (CRO) were noted. The initial empiric antibiotic 
chosen, antibiotics after the susceptibility of the isolate was known and after clinical 
stabilisation were noted. Data on complications like emphysematous 
pyelonephritis, renal abscess, haemodialysis and hospital acquired infections were 
noted and described. We also documented any surgical or radiology guided 
interventional procedures.  
Economic Data 
The economic data included their occupation, education, family income per month 
and participants were then stratified into the respective socio-economic class based 
on the modified Kuppusamy score. The total duration of hospital stay and the 
duration of antibiotics were also noted. The quality of life was assessed by the WHO 
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quality of life questionnaire.  We used a societal perspective on costs to include 
both the health care costs as well as patient related costs. We used the consolidated 
health economic evaluation reporting standards (CHEERS) guidelines to report the 
data. (Appendix-9) 
Figure 6 Study Outline 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pyelonephritis admitted in ward 
Diabetics 
Non-
Diabetics 
Total medical cost- (Direct medical and non-medical+ indirect) 
No of patients with ESBL Pyelonephritis 
No of patients with complications 
Intangible costs 
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The participants were then interviewed regarding direct medical, non-medical and 
indirect costs. (Cost figure shown below) This was done twice, once at admission 
and another through a telephonic interview at the completion of therapy. The direct 
medical costs included bed charges, charges for laboratory investigations, invasive 
and non-invasive tests, drugs and professional charges. The direct non-medical 
costs included expenditure for travel of the patient and the relatives, food during 
hospital stay for the patient and relative and accommodation for the relatives. In-
direct medical costs included loss of wages for the patient and the relative during 
the time of illness.  Our time horizon was only the year of the study and as we did 
not have costs beyond this time period we did not discount costs. 
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Figure 7 Cost Figure 
 
 
 
 
 
 
 
 
 
 
Outcomes: 
 
 
 
 
 
 
Total Cost 
Direct Cost Indirect cost 
Direct medical costs Direct Non-medical costs 
Loss of Wages 
Loss of relatives 
wages 
 
Travel  
Accommodation 
Food  
Communication 
In Patient 
 Bed charges 
 Professional charges 
 Investigations 
 Drugs 
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The primary outcome was total cost of illness for an admission for Pyelonephritis which 
is the direct medical, non-medical cost and the indirect costs.  
The secondary outcomes included comparison of costs among participants with and 
without ESBL bacterial pyelonephritis as well as those with and without diabetes 
mellitus. We also studied the clinical outcomes such as cure, condition at discharge, and 
quality of life (assessed by the WHO quality of life questionnaire).(reference) 
STATISTICAL ANALYSIS 
 
Sample size 
The primary objective is total cost of an admission for Pyelonephritis and the 
hypothesis was that Diabetics would have significantly higher cost compared to 
non-diabetics. The total cost for a single admission for Pyelonephritis was 
estimated to be Rs. 40,000. The Standard deviation was estimated to be 4000. 
The precision (d) was taken as 1000.  The sample size was calculated to be 64.  
Sample Size = [(Zα)2 X SD2]/ d2 = 22x 40002/10002= 64 
 Assuming loss to follow up, a sample size of 75 was taken.     
Data Management 
All data were collected by the principle investigator on the study CRF and then entered 
in Epidata 3.1 software. This was exported for analysis to SPSS version 17, IBM 
Corporation. All data analysis was performed by a biostatistician (1) 
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Data analysis 
All normally distributed data were described using mean and standard deviation 
while non-normally distributed data by median and inter-quartile range. 
Qualitative data were described using counts and percentages.  
 Data was screened for outliers and extreme values using Box-Cox plot and 
histogram (for shape of the distribution). Summary statistics was used for 
reporting demographic and clinical characteristics.  Students t-test will be used 
for analysis of continuous data with Normal distribution and Mann-Whitney U 
test for data with non- Normal distribution. Chi-square test will be performed 
for categorical variables and the variables which will be significant at bivariate 
analysis will be accessed by multivariate analysis. Cost analysis of 
Pyelonephritis was done between those with and without diabetes mellitus, with 
and without ESBL bacterial infections.  
All data were reported with 95% confidence intervals. Differences were 
considered significant at p<0.05.  
Funding and approval 
 
The study was funded by an internal grant of the Hospital called the Fluid grant (22 Z 
240)  (appendix 4) 
 
 
 
P a g e 51 | 125 
 
RESULTS 
 
Figure 2 Strobe figure  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total number of patients admitted in 
CMC vellore (March 2016- July 2017)= 
110311 
Number of patients admitted in 
General medical wards (March 2016- 
July 2017)=  10288 (9.3%) 
Number of patients admitted 
with Pyelonephritis= 456 (4.4%) 
Number of 
Diabetics= 61 
(66.3%) 
Number of non-
Diabetics= 31 
(33.6%) 
Number of ESBL 
Pyelonephritis= 49 
(53.3%) 
Number of non- ESBL 
Pyelonephritis= 35 
(38.0%) 
Number of patients included in 
the study= 92  (20.2%) 
Enterococcus 
species= 6 
Staphylococcus 
aureus= 1 
Candida 
species= 1 
 
Excluded  
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Between March 2016 and July 2017, eligible patients were screened and 92 patients 
were included in the study. The average age was 55.8. Around two thirds of them 
were diabetics. More than half of the women were postmenopausal and a fifth of them 
had urinary incontinence. 12% of the patients had hypotension at presentation.  The 
mean duration of hospital stay was around 12 days and the mean number of days of 
intravenous antibiotics was around 14 days. There were 6 deaths among the patients in 
the study which amounted to 6.5% of the study population. 
 
Table 2 Baseline Characteristics of all patients 
 
Baseline characteristics N= 92 Percentage 
Male 39 42.4% 
Female 53 57.6% 
Average Age 55.8 SD- 16.53 
Diabetes 61 66.3% 
Average HbA1c 8.72 SD- 1.9 
Hypertension 42 45.7% 
Average creatinine 2.2 
Median IQR- (0.82-
3.08) 
Ischaemic Heart disease 15 16.3% 
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Hypotension at 
presentation 
11 12.0% 
Post-menopausal  33 (33/53) 62.3% 
Urinary incontinence 10 (10/53) 18.9% 
Benign prostatic 
hypertrophy 
7 (7/39) 17.9% 
Duration of hospital stay 11.89 Median IQR (7.0-15.0) 
Number of days of 
intravenous antibiotic  
13.99 Median IQR (7.0-14.0) 
Number of deaths  6 6.5% 
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Figure 3 Distribution of Socio-economic status 
 
 
One third of the study population was from lower middle socio-economic status by the 
kuppusamy scale while another third was from the upper lower socio-economic status.  
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Figure 4 Distribution of Monthly Family Income 
 
Costs in INR 
 
The distribution of monthly family income showed that predominantly the study 
population was from the middle socio-economic status.  
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Figure 5 Distribution of Organisms isolated 
 
 
Escherichia coli was the most common organism isolated followed by Enterococcus 
and Klebsiella. 53.3% of the gram negative isolated were producing extended 
spectrum beta lactamases.  
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Table 3 Comparison of baseline characteristics of Diabetics versus Non-Diabetics 
Baseline characteristics Diabetics Non-Diabetics 
Male 24 (26.0%) 15 (16.3%) 
Female 37 (40.2%) 16 (17.3%) 
Average Age 58.8 (SD-12.5)  49.9 (SD- 21.5) 
Average HbA1c 9.3 (SD- 2.7) 5.9 (SD- 0.7) 
Hypertension 35 (38.0%) 7 (7.6%) 
Average creatinine 2.3 2.0 
Ischaemic Heart disease 12 (13.0) 3 (3.2%) 
Hypotension at 
presentation 
11 (12.0%) 0 (0%) 
Duration of hospital stay 12.8 (SD- 7.5) 10.2 (SD- 5.8) 
Number of days of 
intravenous antibiotic  
14.8 (SD- 8.4) 12.3 (SD- 8.4) 
 
Comparing Diabetics and Non-diabetics in the study, the mean age of the diabetics 
was 10 years more than the non-diabetics. All patients who had hypotension were 
diabetics. The diabetics had more comorbidities like hypertension and ischaemic heart 
disease. Renal dysfunction was comparable in both the groups.  
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Table 4  Comparing baseline characteristics of ESBL versus Non- ESBL producing 
organisms 
Baseline characteristics ESBL Non-ESBL 
Male 26 (30.9%) 11 (13.1%) 
Female 25 (29.8%) 24 (28.6%) 
Average Age 57.5 (SD- 13.6) 53.5 (SD- 19.8) 
Diabetes 34 (69.4%) 24 (68.5%) 
Average HbA1c 8.9 8.4 
Hypertension 24 14 
Average creatinine 2.6 1.8 
Ischaemic Heart disease 8 5 
Hypotension at 
presentation 
8 3 
Duration of hospital stay 12.4 11.5 
Number of days of 
intravenous antibiotics 
15.5 11.8 
 
Comparing Pyelonephritis caused by ESBL versus non-ESBL organisms, both groups 
had comparable age groups and diabetics.  The ESBL group had a worse renal 
function at presentation. The duration of intravenous antibiotics was longer in the 
ESBL group.  
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Table 5Cost Description of cost in Diabetics versus Non-Diabetics (in INR) 
Direct Medical cost 
 Diabetics Non-Diabetics P-value 
Mean 90929.3 66888.3 0.2017 
Median 56332.0 47656.0 0.6437 
Standard Deviation 97442.7 50570.5 - 
Direct Non-medical cost 
 Diabetics Non-Diabetics P-value 
Mean 4838.8 5193.1 0.7089 
Median 3500.0 4520.0 0.2839 
Standard Deviation 4167.1 4524.3 - 
Indirect Medical Cost 
 Diabetics Non-Diabetics P-value 
Mean 424.9 776.8 0.2430 
Median 0.0 0.0 1.0 
Standard Deviation 804.8 2074.5 - 
Overall cost 
 Diabetics Non-Diabetics P-value 
Mean 96193.0 72858.2 0.2284 
Median 60632.0 52547.0 0.6754 
Standard Deviation 99722.2 54720.2 - 
Costs in INR 
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The mean cost of a diabetic with pyelonephritis was Rs.96193.0 and for a non-
Diabetic it was Rs.72858.2. The direct medical cost accounted to Rs.90929.3 for the 
diabetics and Rs.66888.3for a non-Diabetic. 
Figure 6 Comparing Costs between Diabetics and Non-Diabetics 
 
Costs in INR 
 
Direct medical costs accounted to more than 90% of the overall costs in both diabetic 
and non-diabetics. Direct non-medical costs accounted to around 7% in the non-
diabetics group and 5% in the diabetic group. Indirect medical costs were around 1% 
in the non-diabetic group and less than 0.5% in the diabetic group. 
 
 
 
90929.3 (94.5%)
66888.3 (91.8%)
4838.8 (5.0%)
5193.1(7.1%)
424.9 (0.4%)
776.8
(1.1%)
86% 88% 90% 92% 94% 96% 98% 100%
Diabetics
Non-Diabetics
Direct Medical cost Direct Non-Medical cost Indirect medical cost
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Table 6 Cost Description in ESBL producing versus Non-ESBL producing organisms  
Direct Medical cost 
 ESBL Non-ESBL P-value 
Mean 97607.6 50638.3 0.0128 
Median 60945.0 30393.5 0.1018 
Standard Deviation 100050.4 51509.0 - 
Direct Non-medical cost 
 ESBL Non-ESBL P-value 
Mean 5108.1 6323.0 0.3774 
Median 4520.0 3395.0 0.4136 
Standard Deviation 3815.3 8469.7 - 
Indirect Medical Cost 
 ESBL Non-ESBL P-value 
Mean 439.2 1200.0 0.5799 
Median 0.0 0.0 1.0 
Standard Deviation 850.4 2248.6 - 
Overall cost 
 ESBL Non-ESBL P-value 
Mean 103154.9 58161.3 0.0231 
Median 67945.0 34303.5 0.0872 
Standard Deviation 102280.9 61838.4 - 
Costs in INR 
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The overall cost for an admission for pyelonephritis caused by an ESBL producing 
organism was Rs.103154.9 and in comparison, that for non-ESBL producing organism 
was Rs.58161.3 which was statistically significant.  The direct medical cost in a patient 
with pyelonephritis caused by an ESBL producing organism was Rs.97607.6 compared 
to Rs.50638.3 for a non-ESBL producing organism which was also statistically 
significant. 
 
Figure 7 Comparing costs between ESBL and Non-ESBL 
 
Costs in INR 
The direct medical cost contributed close to 95% of the overall cost in the ESBL group 
whereas the non ESBL group it accounted to around 90%. Direct non-medical costs 
accounted to 10% in the Non-ESBL group and 5%in the ESBL group. The indirect costs 
was around 2% in the Non-ESBL group and less than 0.5% in the ESBL group. 
Table 7Four way cost comparison of Diabetics, Non-Diabetics, ESBL and Non-ESBL 
(in INR) 
97607.6 (94.6%)
50638.3(87.1%)
5108.1(4.96%)
6323(10.9%)
439.2
(0.4%)
1200
(2.1%)
80% 82% 84% 86% 88% 90% 92% 94% 96% 98% 100%
ESBL
Non-ESBL
Direct Medical cost Direct Non-Medical cost Indirect medical cost
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Direct Medical Cost 
 
 
Diabetics/ 
ESBL 
Diabetics/ 
Non-ESBL 
Non-
Diabetics/ 
ESBL 
Non-
Diabetics/ 
Non-ESBL 
P-value 
Mean 110726.5 70315.5 71370.0 59166.4 0.060 
Median 74385.0 45255.5 50093.0 47656.0 - 
Standard 
deviation 
115641.5 64007.0 51016.0 47992.6 - 
Direct Non-medical cost  
 
Diabetics/ 
ESBL 
Diabetics/ 
Non-ESBL 
Non-
Diabetics/ 
ESBL 
Non-
Diabetics/ 
Non-ESBL 
P-value 
Mean 5151..9 4571.3 5020.5 4363.3 0.679 
Median 4302.5 3370.0 4545.0 3565.0 - 
Standard 
deviation 
4096.1 4507.2 3297.3 2915.7 - 
Indirect Medical cost  
 
Diabetics/ 
ESBL 
Diabetics/ 
Non-ESBL 
Non-
Diabetics/ 
ESBL 
Non-
Diabetics/ 
Non-ESBL 
P-value 
Mean 489.4 320.0 338.8 1156.4 0.837 
Median 0.0 0.0 0.0 0.0 - 
Standard 
deviation 
872.2 710.7 821.6 2983.2 - 
Overall cost  
 
Diabetics/ 
ESBL 
Diabetics/ 
Non-ESBL 
Non-
Diabetics/ 
ESBL 
Non-
Diabetics/ 
Non-ESBL 
P-value 
 116367.7 75206.8 76729.3 64686.0 0.057 
Mean 78814.5 48213.0 52653.0 51556.0 - 
Median 118138.0 66132.7 52853.1 52875.8 - 
Standard 
deviation 
116367.7 75206.8 76729.3 64686.0 - 
Costs in INR 
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The four way cost comparison between Diabetics/ESBL, Diabetics/ non-ESBL, non-
Diabetics/ESBL and non-Diabetics/ non-ESBL showed that Diabetics/ ESBL had the 
highest mean cost with Rs.116367.7 and Non-Diabetics/ ESBL had the lowest mean 
cost with Rs.64686.0. However the difference by ANOVA was not statistically 
significant.  
 
Figure 8 Complications of Pyelonephritis 
 
 
6 (6.5%) patients had emphysematous pyelonephritis while 15 (16.3%) developed 
renal abscess. 5 (5.4%) required renal replacement therapy.  
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Figure 9 Distribution of complications in Diabetics and Non-Diabetics 
 
 
The complications were predominantly among the diabetics with 5 (83.3%) of the 
patients with emphysematous pyelonephritis 12 (80%) of the patients who developed 
renal abscess and 4 (80%) requiring renal replacement therapy being diabetics.  
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Figure 10 Distribution of complications in ESBL and Non-ESBL 
 
 
The complications were more common among the ESBL group as well. 4 (66%) of 
the patients with emphysematous pyelonephritis, 10 (71.4%) of patients who 
developed renal abscesses and 4 (66.6%) of patients who required renal replacement 
therapy had an ESBL producing organism isolated.  
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Table 8 Baseline Quality of life based on WHO-QOL BREf questionnaire 
 
 Physical 
health 
Psychological 
health 
Social 
relationships 
Environment 
Domain 19.7 15.5 8.9 21.5 
Transformed 
scale 
45.2 36.6 49.5 42.2 
 
 
The overall quality of life was less than 50 on the transformed scale on all domains. 
The psychological health was the most affected.  
 
Figure 11 Overall Quality of life 
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Table 9 Quality of life between Diabetics and Non-Diabetics 
 
 Diabetics Non-Diabetics 
Physical health 43.7 48.3 
Psychological health 37.9 42.8 
Social relationships 47.9 52.4 
Environment 40.1 46.6 
 
 
Comparing the diabetics and the non-diabetics, the diabetics had a poorer quality of 
life and the psychological domain was the most affected.  
 
Figure 12Qualtiy of Life in Diabetics versus Non-Diabetics 
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Table 10 Quality of life between ESBL and Non-ESBL 
 
 ESBL Non-ESBL 
Physical health 43.4 47.4 
Psychological health 37.4 41.3 
Social relationships 48.9 49.3 
Environment 40.2 42.9 
 
 
Comparing the quality of life between the ESBL group and the non-ESBL group the 
ESBL group had a poorer quality of life. The psychological health domain was the 
most affected.   
 
Figure 13 Quality of Life in ESBL Versus Non-ESBL 
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DISCUSSION 
 
Medical illness in India are known to significantly affect the socio-economic health of 
both the patient and his or her family (71).  Catastrophic health expenses are defined as 
40% of family income or 10% of household expenditure. (72) On an average 4.8 % of 
total household consumption expenditure is spent on Out-of-pocket (OOP) health care 
payments.(73) The proportion of households that reported catastrophic health 
expenditure in the NSS survey 2009-2010 was 3.5% (3.3-3.7%). (74) 
The cost of care of diabetes in India has been previously described (75).  This looked at 
the overall costs associated with diabetes including diagnosis, medications, and 
treatment of complications.  
The common reason for in-patient admission for diabetics in India is a urinary tract 
infection. Hence our study evaluated the costs associated with this problem. Urinary 
tract infections associated with ESBL organisms are known to be more severe and 
require expensive antibiotics. Hence we also studied the effect of extended spectrum 
beta lactamase producing organisms in this setting. 
 We have described the cost of a single admission for pyelonephritis in a south Indian 
tertiary care center. The results show that the cost for treating pyelonephritis caused by 
extended spectrum beta lactamase producing organism is significantly higher than a 
non-extended spectrum beta lactamase producing organism. The total cost is roughly 
around 2-3 times that of a monthly income of a middle class family. India’s per capita 
income was Rs.1,10,023.20 (US$ 1680 in 2016). (76)  The monthly per capita 
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expenditure in India is Rs.2630 in urban area and Rs.1430 in rural India. (77) Hence an 
admission for Pyelonephritis is a catastrophic health expenditure in India.  
The predominant contributor to the overall cost was the direct medical cost which 
included bed charges, lab investigations, invasive and non-invasive tests, drugs and 
professional charges.  
Comparison of costs from other studies 
 
Comparing our data with the data from a survey in the United States in 2005, the annual 
societal cost for treatment of pyelonephritis was $US 2.14 billion ($US 3.04 billion in 
2017, Rs.199.09 billion) and inpatient cost for a single patient was $US 8315.02 ($US 
11819.98 Costs in 2017 are 42.2% higher than in 2000, Rs.7,74,090.49). (78) Though 
our costs were around 6 times lower than the cost in the United States the economic 
burden on a middle class family is huge. This is partly because the burden is borne by 
the family from savings or debt. Earlier in 1990, the annual societal cost in the United 
States was US$ 1.6 billion. (79) (3 billion US$ in 2017, Prices in 2017 are 87.3% higher 
than in 1990, Rs.196.47 billion). 
Data from the Medicare diagnosis related reimbursement group in the United States in 
1999 reported estimated inpatient costs of $US 2381.28 ($US 3498.82 in 2017, Prices 
in 2017 are 46.9% more than in 1999, Rs.2,29,137.72) without comorbidities and $US 
3352.65 ($US 4926.06 in 2017, Rs.3,22,607.67)  with comorbidities. (80) 
Data from 1995 in the United States reported annual cost of  $US 1594 million ($US 
2560.29 in 2017, Prices in 2017 are 60.6% higher than in 1995, Rs.1,67,673.39) (81) 
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An Australian study described cost of pyelonephritis in children in which 12 children 
were admitted and the cost per day was $US 624.14 (Rs.40874.93) per day. However 
the mean duration of hospital stay was only 3 days and only 3 children received 
intravenous antibiotic therapy for more than 7 days. (82) 
 
Cost of Pyelonephritis caused by Extended spectrum beta lactamase producing 
organism 
 
Community acquired extended spectrum beta lactamase producing organisms is on the 
rise as depicted in our study group with more than half of our study population being 
extended spectrum beta lactamase producing. The number of days required for 
intravenous antimicrobial therapy was longer in patients with extended spectrum beta 
lactamase producing organisms and thus the cost also was significantly different. They 
were also sicker at admission and had more complications. The total duration of hospital 
stay was not significantly different between the two groups probably because few of the 
patients who became clinically stable chose the complete the rest of the antimicrobial 
therapy in a local hospital. The cost of treating an ESBL organism producing 
pyelonephritis was $US3658 (Rs.239562.42) in the United States. (83) 
 
Cost of Pyelonephritis in Type 2-Diabetes Mellitus 
 
Diabetics in the study group also had a higher cost though it was not statistically 
significant. A larger sample size may be required to prove the significance. The direct 
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medical costs again contribute significantly to the overall cost. All patients with 
hypotension were diabetics denoting that they were sicker than the non-diabetics at 
presentation. Diabetics as expected had more incidences of complications which lead 
to more invasive therapy, renal replacement therapy and longer anti-microbial therapy. 
This escalated the cost as compared to non- diabetics.  
 
Direct Non-Medical costs 
 
The direct non-medical costs which are often overlooked also contributed to the overall 
costs. This was mainly the travel and the food for the patient and the care-giver. The 
travel was mainly during the initial visit of the patient to the emergency department and 
after discharge. The day to day travel by the care-givers was negligible. We noted that 
our patients though hailing from faraway places do not hire a place to stay to cut down 
on the costs.  
 
Indirect Medical costs 
 
The indirect medical costs included the loss of pay for the patient and loss of wages for 
the caregiver. We also noted that the indirect medical cost was negligible. Many of our 
patients from the lower socio-economic group had a care giver who was not gainfully 
employed to decrease the loss of wages. The patients who had lost wages were below 
the 25th centile. In the data from the United States however the indirect costs were 
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around 35% of the overall cost. (79) In 1995, indirect costs was $US 936 ($US 1503.4 
in 2017, Prices in 2017 are 60.6% higher than in 1995, Rs.98457.67) 
 
Quality of life 
 
One of the strengths of the study was that we attempted to quantify the intangible losses 
in the quality of life. The quality of life was measured in 4 domains and we compared 
with the available Indian data. When we transformed the scores and compared the four 
domains, we noted that the psychological domain was scored lower than the social, 
physical health and the environment domains. We noted that the social domain which 
included social relations and social support was lower than the normal south Indian 
population. (70) We also compared the quality of life between the diabetics and non-
diabetics. The psychological domain scored lower in the diabetics group. Comparing 
the ESBL and the non-ESBL group, again the psychological domain scored lower in 
the ESBL group. This would mean that the patient would take longer time to recover 
mentally and the productivity will ultimately be lesser.  
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LIMITATIONS 
 
Our study had its limitations. The data was reported by the patients or the care-givers 
and there is an element of reporter bias. Since ours is a tertiary care institution, the 
patients admitted may not represent the patient in the community developing 
pyelonephritis. Usually patients with uncomplicated disease preferred to take the 
antimicrobial therapy in a local hospital. Hence the cost may be higher because of the 
referral bias. However this problem of possible under reporting of wages lost is known 
in most economic studies. 
In order to reduce bias we followed the CHEERS checklist for economic studies and 
have followed all their reporting requirements (Appendix-9) 
 
CONCLUSIONS 
 
1. The mean overall cost of a single admission for pyelonephritis was Rs.88,330.2  
2. The mean overall cost of an admission for a patient with Diabetes mellitus with 
Pyelonephritis was Rs.96,193.0 
3. The mean overall cost of patient admitted with Pyelonephritis caused by 
extended spectrum beta-lactamase producing organism was Rs.1,03,154.9 which 
was significantly more than that caused by a non-extended spectrum beta 
lactamase producing organism.  
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APPENDIX-2 Patient Information Sheet 
 
COST OF ACUTE PYELONEPHRITIS IN DIABETES- A COST OF ILLNESS STUDY 
Department of Medicine, 
Christian Medical College, Vellore 
 
PATIENT INFORMATION SHEET 
 
You are invited to be a part of a study which aims to find the cost of 
an admission for Pyelonephritis in Christian Medical College Vellore  
 
What is Pyelonephritis?  
 
Pyelonephritis is infection of the kidneys. It is usually caused by 
bacteria. It is more common in Diabetic patients. It can cause blood 
stream infection and death if untreated. . It requires antibiotics 
through the intravenous route to clear the infection. The infection 
can rarely lead to collection of pus which should be drained out.  
 
What is the background of this study?  
Diabetes is a huge economic burden. The most important 
component of the cost in Diabetic care is hospital admission. 
Pyelonephritis is an important cause of hospital admission in 
diabetics. Diabetic patients have more complications of 
pyelonephritis. The bacteria causing pyelonephritis nowadays has 
grown resistant to the usual antibiotics leading to use of costlier 
antibiotics.  
 
What is the purpose of this study?  
 
The aim of the study is to find the cost of a single admission for 
pyelonephritis. This will help us understand the burden of the 
disease. We also want to study if the cost is different between 
diabetic patients and non-diabetic patients. 
 
If you take part what will you have to do?  
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If you are included in the study, you will be interviewed regarding 
the cost of your treatment for Pyelonephritis. This will include your 
travel, accommodation, medicines, blood and urine tests and loss of 
pay. This will be followed up by an interview by telephone assessing 
the impact of the disease after few weeks.  
 
Can you withdraw from this study after it starts?  
 
Your participation in this study is entirely voluntary and you are also 
free to decide to withdraw permission to participate in this study. 
Your refusal or withdrawal will not affect the standard of care you 
would receive at our institution's health services.  
 
What will happen if you develop any study related injury?  
 
We do not expect any untoward event to occur due to the study as 
there is no intervention required.  
 
Will your personal details be kept confidential?  
 
The results of this study will be published in a medical journal but 
you will not be identified by name in any publication or presentation 
of results.  
 
If you have any further questions, please contact  
- Dr. Ebenezer Daniel,  
Department Of General Medicine,  
Christian Medical College,  
Vellore 632004  
Telephone: 09486906628  
email: ebyatvellore@gmail.com 
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APPENDIX-3 Performa for data collection 
 
1. Name: 
2. Age: 
3. Sex: 
4. Hospital Number:  
5. Place: 
6. Occupation: 
a. Profession   (10) 
b. Semi-Profession  (6) 
c. Clerical, shop owner, farmer (5) 
d. Skilled worker   (4) 
e. Semi-skilled worker  (3) 
f. Un-skilled worker  (2) 
g. Unemployed    (1) 
7. Education 
a. Professional    (7) 
b. Graduate    (6) 
c. Intermediate/post high school diploma (5) 
d. High school    (4)  
e. Middle school    (3)  
f. Primary School    (2) 
g. Illiterate    (1) 
8. Family income per month, Total= 
a. ≥36, 997  (12) 
b. 18,498-36,996   (10) 
c. 13,874-18,497   (6) 
d. 9,249-13,873  (4) 
e. 5547-9248   (3) 
f. 1866-5546   (2) 
g. ≤1865    (1) 
9. Socio-Economic class (Modified Kuppusamy score) 
a. Upper   (26-29) 
b. Upper Middle  (16-25) 
c. Lower Middle  (11-15) 
d. Upper Lower  (5-10) 
e. Lower   (<5) 
10. Duration of Hospital stay-  
11. Diabetes mellitus Type 2- yes/ no 
12. Hba1c-  
13. Hypertensive- yes / no 
14. Creatinine- 
15. Ischaemic Heart disease- yes / no 
16. Previous urological procedures- yes/no 
17. Risk factors for UTI             1. Present   2.Absent 
If present, 
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Uretheral stricture 1.Yes  2. No              
 
Stones             1.Yes  2. No              
 
Urinary catheter 1.Yes  2. No              
 
Vesicoureteral reflux 1.Yes  2. No              
 
Prostatic hypertrophy 1.Yes  2. No              
 
Neurogenic bladder 1.Yes  2. No 
 
18. Clinical symptoms 
a. Fever- Yes/no 
b. Flank pain- Yes/no 
c. Hypotension-Yes/no 
19. For women, 
 
Use of spermicide 1.Yes  2. No              
 
Recent sexual intercourse 1.Yes  2. No              
 
New sexual partner  1.Yes  2. No              
 
UTI in the past 1 year 1.Yes  2. No              
 
Pregnancy 1.Yes  2. No              
 
Post menopausal 1.Yes  2. No              
 
Urinary incontinence 1.Yes  2. No              
 
Cystocele 1.Yes  2. No              
 
1st UTI < 15 years of age  1.Yes  2. No   
 
Maternal history of UTI    1.Yes  2. No 
 
 
20. Urine Routine- 
WBC  - 
RBC   - 
Nitrite:   1. Positive   2. Negative 
Leucocyte esterase  1. Positive   2. Negative 
 
 
 
21. Blood Culture- 
a. Organism- 
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b. No. Of colonies 
c. ESBL- Yes/no 
d. CRO- Yes/ No 
 
22. Urine culture- 
a. No. of colonies- 
b. Organism- 
c. ESBL- Yes/no 
d. CRO- Yes/ no 
 
23. Antibiotic used 
a. Empirical 
b. After culture reports 
c. After clinical stabilisation- 
24. No. of days of Intravenous antibiotics 
25. Complications 
a. Emphysematous Pyelnoephritis- Yes/no 
b. Renal abscess-- Yes/no 
c. Dialysis- Yes/no 
d. Hospital acquired infections- yes/no 
26. Intervention- - Yes/no 
a. Radiological- Yes/no 
b. surgical- Yes/no 
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27. Direct Medical Costs 
a. In-patient: 
i. Bed charges: 
ii. Investigations  
1. Lab investigations:  
2. Non-invasive tests: 
3. Invasive tests: 
iii. Drugs: 
iv. Professional charges: 
28. Direct Non-medical costs 
a. Travel: 
i. Per travel 
ii. No. of relatives 
iii. Total 
b. Food: 
i. Per day 
ii. No. of relatives 
iii. Total  
c. Accomodation: 
i. Per day 
ii. No. of relatives 
iii. Total  
29. Indirect Medical costs 
a. Loss of pay: 
b. Loss of Relative’s wages: 
30. How was the money arranged? 
a. Savings 
b. Debt 
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APPENDIX- 4- Approval for Fund by the Institutional Review 
Board 
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APPENDIX-5 WHO Quality of Life Questionnaire 
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APPENDIX- 6 User Agreement for using the WHO Quality of life 
Questionnaire 
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APPENDIX-7Abstract 
 
COST OF PYELONEPHRITIS IN TYPE- 2 DIABETES (COPID 
STUDY) - A COST OF ILLNESS STUDY 
 
Background 
Expenditure for health in India is borne predominantly out-of-pocket costs. A hospital 
admission often drives households to poverty. Diabetes in particular has become a huge 
economic burden in both rural and urban India. Pyelonephritis is a frequent cause of 
admission in a patient with Diabetes. With the rise in the incidence of community 
acquired extended spectrum beta-lactamase producing organisms the cost of illness has 
increased.  
Aim 
To estimate the cost of Acute Pyelonephritis in patients with Type 2 Diabetes mellitus 
admitted in general medical wards   
Objectives 
1. To estimate the total cost of a single admission for  Acute Pyelonephritis    
2. To estimate the difference in cost of admission for Acute Pyelonephritis 
between Diabetics and Non-Diabetics   
3. To find the difference of cost of admission for Acute Pyelonephritis 
caused by ESBL organisms and non-ESBL organisms   
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Methods  
We conducted a prospective observational economic study of patients 18 years and 
above admitted with clinical features suggestive of acute pyelonephritis, laboratory 
evidence of pyuria and a blood culture and/or urine culture growing any uropathogenic 
organism. Participants were recruited from the general medical wards of the Christian 
medical college, Vellore, a tertiary care hospital primarily catering to middle and low 
income group patients from all over India, predominantly the south Indian and the north 
eastern states. We assessed the direct medical, direct non-medical and indirect cost for 
an admission for pyelonephritis. We also assessed the quality of life using the 
WHOQOL BREF questionnaire.  
Findings 
Between March 2016 and July 2017, we screened and included 92 participants for the 
study. The numbers of Diabetics were 61 (66.3%) and the number of pyelonephritis 
caused by an extended spectrum beta lactamase producing organism was 49 (53.3%). 
The mean overall cost of a single admission for pyelonephritis was INR 88,330.2. The 
mean overall cost of an admission for a patient with Diabetes mellitus with 
Pyelonephritis was Rs.96,193.0. The mean overall cost of patient admitted with 
Pyelonephritis caused by extended spectrum beta-lactamase producing organism was 
Rs.1,03,154.9 . The difference in cost between those without Diabetes was (Rs. 24,041, 
P value= 0.2017) and between those with and without ESBL infection was (Rs.46969.3, 
P=0.0128).  The intangible costs as measured by the quality of life showed that the 
psychological and the social domains were particularly lower than general Indian 
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population. The quality of life was lower in patients with Diabetes and patients who had 
pyelonephritis due to an extended spectrum beta lactamase producing organism as 
compared to those without. 
Conclusion 
A single admission for a patient with pyelonephritis is a catastrophic health expenditure 
in the household in India. In this setting, policies should be geared towards preventing 
the vulnerable middle and low economic groups from being driven below the poverty 
line.  
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APPENDIX 8- Data sheet 
 
idno name age sex hospno place occup educat income economic hosstay dm hba1c ht creat ihd pup uti uretheral stones
1 savithri 60 2 111597C Gudiyatham 10 7 6 4 8 1 12 1 0.69 1 0 2 0 0
2 Ramanamma 55 2 532349G Kadappa 1 1 6 2 22 1 6.8 1 0.5 0 0 2 0 0
3 Malliga VS 59 2 875238D Saravanapati, Vellore3 3 10 4 13 1 7.8 1 2.38 1 0 2 0 0
4 Kalavathi D 61 2 290858F Vasur, Vellore 3 4 3 2 13 1 7.1 1 0.9 0 0 2 0 0
5 Harikrishna S 42 1 531672G Kallikri, chittoor 3 4 4 3 15 1 11.8 1 5.78 0 1 1 1 0
6 Jayaraman S 67 1 532148G Kanchipuram 6 5 10 4 8 1 12.2 1 3.25 1 0 2 0 0
7 Zeenath Begam 56 2 453344D Melvishanam 3 3 6 3 15 1 9.7 1 4.3 0 0 2 0 0
8 Vanitha S 66 2 532101G Pallikonda 2 2 1 2 11 1 7.4 1 1.69 0 0 2 0 0
9 Rathinam 75 2 530448G Kaspa 6 6 6 4 20 1 14.8 0 1.24 0 0 2 0 0
10 Mohan 65 1 527871G Chittoor 3 4 6 3 25 0 7.6 1 1.6 0 1 1 0 1
11 Daniel 65 1 761497G Thirupathur 4 5 10 4 14 1 9.5 1 4.48 0 0 2 0 0
12 Pushparani 60 2 032838D Odukathur 2 3 4 2 32 1 1 2.44 0 0 2 0 0
13 Baby T 19 2 532245G Chittoor 3 6 6 3 5 0 0 0.63 0 0 2 0 0
14 Ramachandran G 59 1 520027G Gudiyatham 3 4 3 2 2 1 7.7 0 1.77 0 0 2 0 0
15 Vijaya kumari 58 2 077470G Chittoor 2 3 4 2 17 0 0 3.2 0 0 2 0 0
16 Sivalingam E 58 1 531930G Odukathur 2 3 2 2 15 1 14.5 1 3.92 0 0 2 0 0
17 Krishnan 32 1 520308G Tiruvanamalai 4 5 6 3 4 0 0 1.82 0 1 1 1 0
18 Balaraman 76 1 977728F Vellore 2 3 6 3 11 0 6 1 6.37 1 0 2 0 0
19 Ravichandran 51 1 272868B Gudiyatham 3 4 4 3 5 1 6.3 0 0.84 0 0 2 0 0
20 Sampath 58 1 920557D Gudiyatham 5 5 10 4 9 1 7.8 0 3.2 0 0 2 0 0
21 Rani 49 2 108605G Vellore 3 3 4 2 6 1 12.8 0 1.82 0 0 2 0 0
22 Narayanan 71 1 534955G Tiruvanamalai 3 3 4 2 7 1 5.1 0 1.05 0 0 1 0 0
23 Senthil 29 1 549611G Tiruvanamalai 4 6 6 4 19 1 6.8 0 0.6 0 0 2 0 0
24 Ramya 23 2 129596B Vellore 4 6 10 4 7 0 0 0.81 0 0 1 0 1
25 Mary 60 2 546636G Ambur 3 4 10 4 25 1 8.4 0 2.41 0 0 1 0 0
26 Kathirvel 82 1 40000 Vellore 4 5 10 4 19 1 8 1 0.91 0 0 2 0 0
27 Kasthuri 64 2 135229G Vellore 3 5 10 4 18 0 6.4 1 1.25 1 0 2 0 0
28 Narayanaswamy 77 1 269641F Gudiyatham 3 3 4 2 13 1 1 1.24 0 0 1 0 0
29 Karpagammal 81 2 561895G Vellore 3 3 4 2 15 0 4.7 0 0.78 0 0 2 0 0
30 Kanagaraj 81 1 539111G Vellore 3 4 10 4 20 1 9 1 3.33 0 0 2 0 0
31 Nirmala 52 2 768263G Vellore 3 5 10 4 5 1 12.5 1 0.59 1 0 2 0 0
32 Gandhimathi 47 2 543376G Tiruvanamalai 3 3 4 2 10 1 12.4 1 2.02 0 0 2 0 0
33 Mahalakshmi 32 2 520911F Vellore 3 3 3 2 4 0 0 1.13 0 0 2 0 0
34 Karpagammal 81 2 561895G Vellore 2 2 6 2 14 0 0 0.78 0 0 2 0 0
35 Govindaswamy 55 1 522622F Ponna 2 2 3 2 8 1 5.2 0 0.74 0 0 1 1 0
36 Bhuvaneshwari 67 2 701257A Vellore 3 3 6 3 9 1 6.4 1 0.38 1 0 2 0 0
37 Vasundra 18 2 523413G cuddalore 6 6 12 4 5 0 6.3 0 0.63 0 0 2 0 0
38 Deepika 18 2 523279G Anaicut 4 5 10 4 11 0 0 1.86 0 0 2 0 0
39 Sivalingam 51 1 531930G Anaicut 4 5 6 3 15 1 14.5 1 1.89 1 0 2 0 0
40 Mohan 54 1 210131D Vellore 3 4 6 3 7 1 7.3 1 1.36 1 0 2 0 0
41 Ramakrishnappa 65 1 994180F Chittoor 4 5 10 4 5 0 6 0 1.34 0 0 1 0 0
42 Nagaraj 72 1 070053D Vellore 2 3 4 3 8 0 5.6 1 1.67 0 0 1 0 0
43 Chinni 44 2 704238F chittoor 3 3 3 2 6 1 6.3 1 1.39 0 0 2 0 0
44 Jayaraman 68 1 532148G Kanchipuram 3 4 4 3 8 1 12.2 1 3.25 1 0 2 0 0
45 Parvathi 58 2 406448F Walajapet 3 4 10 4 8 0 1 0.57 0 0 2 0 0
46 Sanjeevi Reddy 57 1 548471G Chittoor 4 5 10 4 25 0 0 0.79 0 0 2 0 0
47 Elayaraja 51 1 510762G Salem 4 5 10 4 13 0 0 3.75 0 0 2 0 0
48 Gnanasekaran 60 1 774771C Vellore 4 4 6 3 11 0 0 6.43 0 0 1 0 1
49 Vinodh 18 1 195098D Vellore 1 2 2 1 8 0 0 0.26 0 0 2 0 0
50 Umapaty 60 1 527395G Vellore 3 3 3 2 3 1 14.9 1 3.12 0 0 2 0 0
51 Kanchana 44 2 564736G Katpadi 3 5 10 4 10 1 11.4 0 0.92 0 0 2 0 0
52 Indirani 74 2 354443B Rangapuram, Vellore1 1 2 1 7 1 6.3 1 1.02 0 0 1 0 0
53 Mani R 67 1 530381D Kamavanpettai 2 3 4 2 11 0 6 1 1.2 1 0 2 0 0
54 Selvi 50 2 510501G Vellore 3 3 4 2 7 1 10.5 0 0.36 0 0 2 0 0
55 Radha 68 2 270813B Vellore 3 3 4 2 5 1 11.8 1 0.58 1 0 2 0 0
56 Jammunabai 63 2 539680G Vellore 3 3 4 2 18 1 8 1 0.89 0 0 2 0 0
57 Jayachandran 49 1 531883G Vellore 6 6 10 4 19 1 7.8 0 7.7 0 0 2 0 0
58 Jeevaratna 61 2 693126D Chittoor 3 3 6 3 28 1 0 0 0 2 0 0
59 Amithammal 70 2 526261G Kaverikuppam 2 1 1 1 18 1 1 8.36 0 0 2 0 0
60 Pavithra 26 2 331326F Vellore 4 6 6 4 7 0 5.7 0 3.13 0 0 2 0 0
61 Anandhan 52 1 108798G Chittoor 3 4 6 3 6 0 0 7.69 0 0 2 0 0
62 Kalaiselvi 26 2 913318D Vellore 4 6 10 4 9 0 0 0.95 0 0 1 0 0
63 Mumtaj 49 2 557355G Vellore 3 3 6 3 6 1 6.5 0 0.72 0 0 2 0 0
64 Jayanthi 37 2 501626G Vellore 3 3 6 3 14 1 6.7 0 0.71 0 0 2 0 0
65 Noorjahan 57 2 518193G Chittoor 3 4 6 3 10 1 7.1 0 2.01 0 0 2 0 0
66 Saroja 64 2 402912G Chennai 3 3 6 3 14 1 12.4 0 0.82 0 0 2 0 0
67 Joshuva 74 1 559092G Vellore 4 4 6 3 5 0 5.9 0 0.92 0 0 2 0 0
68 Gunasundari 23 2 990483F Arcot 3 4 6 3 13 0 0 0.31 0 0 1 0 0
69 Marry 50 2 669415G Tiruvanamalai 4 3 6 3 8 1 10.8 1 1.42 1 0 2 0 0
70 Bakiyavathi 53 2 559285G Vellore 4 4 6 3 12 0 5.1 0 1.29 0 0 2 0 0
71 Bharathi 61 2 440759D Vellore 1 3 4 2 7 0 5.7 1 1.08 0 0 2 0 0
72 Munaswamy 57 1 514167F Chittoor 3 4 3 2 7 1 8.1 0 2.83 0 0 2 0 0
73 Anitha 27 2 549050G Ranipet 3 3 3 2 6 1 10 0 1.04 0 0 2 0 0
74 Ellamal 80 2 541355G Tiruvanamalai 3 3 3 2 3 1 7.4 0 0.5 0 0 2 0 0
75 Muthu 59 1 544004G Tiruvanamalai 2 3 3 2 18 0 0 1.64 0 0 2 0 0
76 Balagangiah 56 1 530423G Kadappa 4 6 2 3 33 1 6 1 1.68 1 0 1 0 0
77 Ananthammal 66 2 523162G Thiruvallur 3 3 4 2 4 1 12.2 0 0.67 0 0 2 0 0
78 Vishwanath Reddy 71 1 321022D Chittoor 3 5 6 3 5 0 0 1.46 0 0 2 0 0
79 Balamma 50 2 643543G Ranipet 2 3 3 2 7 1 7.1 1 3.08 0 0 1 0 0
80 Ambika 33 2 776432C Gudiyatham 3 5 6 3 7 1 1 8.49 0 0 2 0 0
81 Pandian 61 1 457913D Vellore 4 4 6 3 17 1 0 2.98 0 0 2 0 0
82 Suseela 64 2 942334F Arcot 3 4 6 3 15 1 10.6 1 1.1 0 0 2 0 0
83 Jebamalai 85 1 853093A Vellore 4 3 6 3 17 1 7 1 1.52 0 0 2 0 0
84 Thiruvarangam 63 1 675695B Tiruvanamalai 4 4 6 3 31 1 1 5.91 0 0 2 0 1
85 Gnanasekaran 65 1 774771C Timiri, Kavalur, Arcot2 4 3 2 4 0 0 6.43 0 1 1 0 1
86 Aparna 21 2 237445G Ambur 1 6 4 3 5 0 0 0.47 0 0 2 0 0
87 Annamalai 76 1 530307G Kalambur, Tiruvanamalai3 3 10 4 14 1 10.7 0 6.6 0 0 2 0 0
88 Isha 68 2 294860 Viruthampet, Vellore1 2 10 3 8 1 9.1 1 1.49 0 0 2 0 0
89 Rukminamma J 60 2 530476G Rajakandama, Tirupati1 1 4 2 20 1 8.1 0 1.72 0 0 2 0 0
90 Parvathi 49 2 526905G Amundi 2 3 2 2 27 1 8.6 0 4.82 0 0 2 0 0
91 Rajeshwari 73 2 526495G Arcot 3 2 6 3 5 1 11.5 1 1.77 0 0 2 0 0
92 Malliga 45 2 531606G Thirupathur 1 3 3 2 11 1 11.8 0 2.73 1 0 2 0 0
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urinary vesireflux prostatic neurogenic fever flankpain hypotensin spermicide sexual newsexual utipast preg postmeno urinaryin cystocele uti1st materuti wbc rbc
0 0 0 0 1 1 0 0 0 0 1 0 1 1 0 0 0 40 1
0 0 0 0 1 1 0 0 0 0 1 0 1 1 1 0 0 241 4
1 0 0 0 1 1 1 0 0 0 0 0 1 0 0 0 0 58 13
0 0 0 0 1 1 0 0 0 0 0 0 1 1 0 0 0 27 14
1 0 1 0 1 1 0 353 41
0 0 0 0 1 1 0
0 0 0 0 1 1 0 0 0 0 1 0 1 0 0 0 0 610 29
1 0 0 0 1 1 0 0 0 0 0 0 1 1 0 0 0 75 143
1 0 0 0 0 1 0 0 0 0 0 0 1 1 0 0 0 47 3
1 0 0 0 1 0 0 16 16
0 0 0 0 1 1 1 18 14
0 0 0 0 1 1 1 0 0 0 0 0 1 0 0 0 0 2584 22
0 0 0 0 1 1 0 0 1 1 0 1 0 0 0 0 0 16 3
0 0 0 0 1 1 1 119 2
0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 171 5
0 0 0 0 1 1 1 620 10
0 0 0 0 1 1 0 195 20
0 0 0 0 1 1 0
0 0 0 0 1 1 0 676 9
0 0 1 0 1 1 0 126 7
0 0 0 0 1 1 0 0 0 0 0 0 1 0 0 0 0 9 4
0 0 1 0 1 1 0 51 13
0 0 0 0 1 1 1 115 7
0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 7 5
1 0 0 0 1 1 0 0 0 0 0 0 1 0 0 0 0 90 5
0 0 0 0 1 1 0 236 4
0 0 0 0 1 1 0 0 0 0 0 0 1 0 0 0 0
1 0 0 0 1 1 0 9
0 0 0 0 1 1 0 0 0 0 0 0 1 0 0 0 0 804 21
0 0 0 0 1 1 0 81 46
0 0 0 0 1 1 0 0 0 0 0 0 1 0 0 0 0 263 9
0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 10
0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 20 7
0 0 0 0 1 1 0 0 0 0 0 0 1 1 0 0 0 804 21
0 0 0 0 1 1 0 397 10
0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 363 5
0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 149 2
0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 177 13
0 0 0 0 1 1 0 620 10
0 0 0 0 1 1 1 454 4
0 0 1 0 1 1 0 709 15
0 0 1 0 1 1 0 14 21
0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 185 17
0 0 0 0 1 1 0 262 5
0 0 0 0 1 1 0 0 0 0 0 0 1 0 0 0 0 1046 22
0 0 0 0 1 1 0 82 944
0 0 0 0 1 1 0 8172 80
0 0 0 0 1 1 0 108 24
0 0 0 0 0 0 0 489 47
0 0 0 0 1 1 1 4 25
0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 72 3
1 0 0 0 0 1 0 0 0 0 1 0 1 1 0 0 0 285 2
0 0 0 0 1 1 0 23 4
0 0 0 0 1 1 0 0 0 0 0 0 1 0 0 0 0 61 11
0 0 0 0 1 1 0 0 0 0 0 0 1 0 0 0 0 15 11
0 0 0 0 1 1 1 0 0 0 0 0 1 0 0 0 0 581 5
0 0 0 0 1 1 0 23 19
0 0 0 0 1 1 0 0 0 0 0 0 1 0 0 0 0 18 4
0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 5231 658
0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 173 221
0 0 0 0 1 1 0 38 9
0 0 0 0 1 1 0 0 0 0 0 1 0 0 0 0 0 630 10
0 0 0 0 1 1 0 0 0 0 0 0 1 0 0 0 0 91 2
0 0 0 0 1 1 0 0 0 0 1 0 0 0 0 0 0 350 4
0 0 0 0 1 1 0 0 0 0 0 0 1 0 0 0 0 840 4
0 0 0 0 1 1 0 0 0 0 0 0 1 1 0 0 0 984 15
0 0 1 0 1 1 0 163 3
0 0 0 0 1 1 0 0 0 0 0 1 0 0 0 0 0 60 2
0 0 0 0 1 1 0 0 0 0 0 0 1 0 0 0 0 47 30
0 0 0 0 1 1 0 0 0 0 0 0 1 0 0 0 0 378 19
0 0 0 0 1 1 0 0 0 0 0 0 1 1 0 0 0 161 424
0 0 0 0 1 1 1 140 12
0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 13 5
0 0 0 0 1 1 0 0 0 0 0 0 1 0 0 0 0 149 21
0 0 0 0 1 1 0 159 16
1 0 0 0 1 1 0 490 4
0 0 0 0 1 1 0 0 0 0 0 0 1 1 0 0 0 1
0 0 0 0 1 1 0 208 5
0 0 0 0 1 1 0 0 0 0 0 0 1 0 1 0 0 28 4
0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 1285 10
0 0 0 0 1 1 0 52 1
0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 214 13
0 0 1 0 1 1 0 89 61
0 0 0 0 1 1 0
1 0 0 0 1 1 0 24 15
0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 114 17
0 0 0 0 1 1 0 369 486
0 0 0 0 1 1 1 0 0 0 0 0 1 0 0 0 0 2610 45
0 0 0 0 1 1 0 0 0 0 0 0 1 0 0 0 0 49 3
0 0 0 0 1 1 0 0 0 0 0 0 1 0 0 0 0 1568 2329
0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 1 1 4890 6
0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 368 5
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nitrite leucocyte bccolonies bcorgan bcesbl bcro uccolonies ucorgan ucesbl ucro empirical atrculture atrclinica venousdaysemphypyel renal dialysis hosinfect interventi radiologic
2 1 E.coli 1 0 10 E.coli 1 0 MeropenemMeropenemMeropenem 14 0 0 0 0 0 0
2 1 E.coli 1 0 10 E.coli 1 0 MeropenemMeropenemMeropenem 22 0 1 0 0 1 1
2 1 E.coli 1 0 10 E.coli 1 0 MeropenemMeropenemMeropenem 42 0 1 0 0 0 0
2 1 E.coli 1 0 10 E.coli 1 0 Ertapenem MeropenemMeropenem 14 0 0 0 0 0 0
2 1 E.coli 0 0 10 E.coli 0 0 MeropenemPiperacillin tazobactumPiper cillin tazobactum10 0 0 0 0 0 0
No growth 1 E.coli 1 0 MeropenemMeropenemMeropenem 16 0 0 0 0 0 0
2 1 E.coli 1 0 10 E.coli 1 0 MeropenemMeropenemMeropenem 24 0 0 0 0 0 0
2 1 No growth 1 Enterococcus 0 0 MeropenemPiperacillin tazobactum / LinezolidLinezolid 14 0 0 0 0 0 0
2 1 No growth 10 Enterococcus 0 0 Piperacillin tazobactumLinezolid Linezolid 14 0 0 0 0 0 0
2 1 E.coli 0 1 10 E.coli 0 1 MeropenemColistin / RifampicinColistin / Rifampicin25 1 0 0 0 0 0
1 1 E.coli 1 0 10 E.coli 1 0 MeropenemMeropenemMeropenem 20 0 1 0 0 0 0
2 1 No growth 10 E.coli 1 0 MeropenemMeropenemMeropenem 14 0 1 0 0 0 0
2 1 No growth 10 E.coli 1 0 Piperacillin tazobactumErtapenem Ertapenem 10 0 0 0 0 0 0
2 1 E.coli 1 0 10 E.coli 1 0 MeropenemMeropenemMeropenem 7 0 0 0 0 0 0
2 1 No growth 1 E.coli 1 0 MeropenemMeropenemMeropenem 14 0 0 0 0 0 0
1 1 No growth 10 E.coli 1 0 MeropenemMeropenemMeropenem 14 0 0 0 0 1 0
1 1 E.coli 1 0 10 E.coli 1 0 MeropenemErtapenem Ertapenem 14 0 0 0 0 0 0
E.coli 0 1 10 E.coli 0 1 MeropenemColistin / MeropenemColisti  / Meropenem14 0 1 0 0 0 0
2 1 No growth 10 Klebsiella 0 0 Piperacillin tazobactumciprofloxacinciprofloxacin 13 0 0 0 0 0 0
2 1 No growth 1 Enterococcus 0 0 Piperacillin tazobactumAmpicillin Ampicillin 14 0 0 0 0 0 0
1 1 E.coli 1 1 1 E.coli 1 1 Piperacillin tazobactumColistin / MeropenemColisti  / Meropenem7 0 0 0 0 0 0
1 1 No growth 1 E.coli 1 0 MeropenemMeropenemMeropenem 7 0 0 0 0 0 0
2 1 No growth 1 Enterococcus 0 0 MeropenemLinezolid Linezolid 10 0 0 1 0 0 0
2 1 E.coli 0 0 10 E.coli 0 0 Piperacillin tazobactumCiprofloxacinCiprofloxacin 7 0 0 0 0 0 0
2 1 Enterococcus 0 0 1 Enterococcus 0 0 MeropenemLinezolid Linezolid 14 0 0 0 0 0 0
1 1 E.coli 1 0 10 E.coli 1 0 MeropenemMeropenemMeropenem 14 0 0 0 0 0 0
E.coli 1 0 1 E.coli 1 0 MeropenemMeropenemMeropenem 14 0 0 0 0 0 0
2 1 No growth 10 E.coli 1 0 MeropenemMeropenemMeropenem 14 0 0 0 0 0 0
2 1 E.coli 0 0 1 E.coli 0 0 MeropenemPiperacillin tazobactumPiper cillin tazobactum7 0 0 0 0 0 0
2 1 E.coli 1 0 10 E.coli 1 0 MeropenemMeropenemMeropenem 25 1 0 0 0 0 0
2 1 No growth Piperacillin tazobactumPiper cillin tazobactumPiper cillin tazobactum7 0 0 0 0 0 0
2 1 E.coli 1 0 10 E.coli 1 0 MeropenemMeropenemMeropenem 10 0 0 0 0 0 0
1 1 No growth 10 Klebsiella 0 0 Piperacillin tazobactumPiper cillin tazobactumPiper cillin tazobactum7 0 0 0 0 0 0
2 1 E.coli 0 0 10 E.coli 0 0 Piperacillin tazobactumPiper cillin tazobactumPiper cillin tazobactum14 0 0 0 0 0 0
1 1 No growth 10 E.coli 0 0 Piperacillin tazobactumPiper cillin tazobactumPiper cillin tazobactum7 0 0 0 0 0 0
1 1 E.coli 0 0 10 E.coli 0 0 MeropenemCiprofloxacinCiprofloxacin 6 0 0 0 0 0 0
1 1 No growth Piperacillin tazobactumPiper cillin tazobactumPiper cillin tazobactum7 0 0 0 0 0 0
2 1 E.coli 0 0 10 E.coli 0 0 MeropenemAmikacin Amikacin 14 0 0 0 0 0 0
1 1 No growth 10 E.coli 1 0 MeropenemMeropenemMeropenem 14 0 0 0 0 0 0
2 1 E.coli 0 0 10 E.coli 0 0 MeropenemPiperacillin tazobactumPiper cillin tazobactum14 0 0 0 0 0 0
1 1 E.coli 1 0 1 E.coli 1 0 MeropenemMeropenemMeropenem 14 0 0 0 0 0 0
1 1 No growth 10 E.coli 1 0 MeropenemPiperacillin tazobactumPiper cillin tazobactum7 0 0 0 0 0 0
1 1 No growth 1 E.coli 0 0 MeropenemMeropenemLevofloxacin 14 0 0 0 0 0 0
2 1 No growth MeropenemMeropenemMeropenem 14 0 0 0 0 0 0
1 1 No growth 10 E.coli 1 0 MeropenemMeropenemMeropenem 7 0 0 0 0 0 0
2 1 No growth MeropenemMeropenemMeropenem 42 0 1 0 0 0 0
2 1 No growth 10 E.coli 1 0 MeropenemMeropenemMeropenem 7 0 0 0 0 0 0
2 1 E.coli 1 0 10 E.coli 1 0 MeropenemMeropenemErtapenem 28 0 0 0 0 1 1
2 1 No growth 10 E.coli 1 0 Piperacillin tazobactumMeropene Meropenem 11 0 0 0 0 0 0
2 2 E.coli 1 0 10 Candida 0 0 MeropenemMeropenemMeropenem 3 0 0 0 0 0 0
2 1 No growth 1 Staphylococcus aureus0 0 MeropenemMeropenemMeropenem 10 0 0 0 0 0 0
1 1 No growth MeropenemMeropenemMeropenem 7 0 0 0 0 0 0
1 1 No growth 10 E.coli 0 0 MeropenemMeropenemCiprofloxacin 7 0 0 0 0 0 0
2 1 E.coli 1 0 10 E.coli 1 0 MeropenemMeropenemErtapenem 14 0 0 0 0 0 0
2 1 No growth 10 E.coli 0 0 MeropenemCiprofloxacinCiprofloxacin 4 0 0 0 0 0 0
2 1 Klebsiella 0 0 10 Klebsiella 0 0 MeropenemCiprofloxacinCiprofloxacin 31 0 1 0 0 1 1
2 1 No growth 10 E.coli 1 0 MeropenemMeropenem / LinezolidMeropenem / Linezolid14 1 1 1 0 0 0
1 1 Klebsiella 0 0 1 Enterococcus , Klebsiella0 0 Piperacillin tazobactumPiper cillin tazobactumPiper cillin tazobactum26 1 0 0 0 1 1
2 1 No growth 1 E.coli 1 0 MeropenemMeropenemMeropenem 14 0 0 0 0 0 0
2 1 No growth 10 E.coli 0 0 MeropenemCiprofloxacinCiprofloxacin 3 0 0 0 0 0 0
2 1 E.coli 1 0 1 E.coli 1 0 Piperacillin tazobactumMeropene Meropenem 6 0 0 0 0 0 0
2 1 No growth 10 E.coli 0 0 MeropenemPiperacillin tazobactumCiprofloxacin 4 0 0 0 0 0 0
2 1 E.coli 1 0 10 E.coli 1 0 Piperacillin tazobactumMeropene Meropenem 14 0 0 0 0 0 0
2 1 E.coli 0 0 1 E.coli 0 0 MeropenemAmikacin Amikacin 14 0 1 0 0 0 0
2 1 E.coli 1 0 10 E.coli 1 1 MeropenemColistin / MeropenemColisti  / Meropenem14 1 0 0 0 1 0
1 1 No growth 10 E.coli 0 0 MeropenemCiprofloxacinCiprofloxacin 14 0 0 0 0 0 0
2 1 No growth 10 E.coli 1 0 MeropenemMeropenemMeropenem 7 0 0 0 0 0 0
2 1 No growth 10 E.coli 1 0 MeropenemMeropenemMeropenem 10 0 0 0 0 0 0
2 1 No growth 1 E.coli 1 0 MeropenemMeropenemMeropenem 10 0 0 0 0 0 0
1 1 No growth Pseudocitrobacter faecalis1 0 MeropenemMeropenemErtapenem 28 0 1 0 0 0 0
2 1 No growth MeropenemMeropenemMeropenem 7 0 0 0 0 0 0
2 1 E.coli 1 0 10 E.coli 1 0 MeropenemMeropenemMeropenem 14 0 0 0 0 0 0
2 1 E.coli 0 0 10 E.coli 0 0 Piperacillin tazobactumPiper cillin tazobactumPiper cillin tazobactum17 0 1 0 0 0 0
2 1 No growth 10 Pseudomonas 0 0 MeropenemMeropenemMeropenem 3 0 0 0 0 0 0
1 1 E.coli 1 0 10 E.coli 1 0 MeropenemMeropenemMeropenem 14 0 0 1 0 0 0
2 1 No growth Klebsiella 1 0 MeropenemMeropenemMeropenem 42 0 1 0 1 0 0
1 1 E.coli 1 0 Piperacillin tazobactumPiper cillin tazobactumPiper cillin tazobactum14 0 0 0 0 0 0
1 1 No growth 10 E.coli 1 0 Ertapenem Ertapenem Ertapenem 4 0 0 0 0 0 0
2 1 E.coli 1 0 Piperacillin tazobactumPiper cillin tazobactumPiper cillin tazobactum7 0 0 0 0 0 0
1 1 No growth 10 E.coli 0 0 MeropenemMeropenemMeropenem 7 0 0 0 0 0 0
1 1 No growth 10 E.coli 1 0 Piperacillin tazobactumPiper cillin tazobactumPiper cillin tazobactum14 0 1 0 0 1 1
2 1 No growth Klebsiella / E.coli 1 0 MeropenemMeropenemMeropenem 14 0 0 0 0 0 0
2 1 E.coli 0 0 10 E.coli 0 0 MeropenemPiperacillin tazobactumPiper cillin tazobactum14 0 0 0 0 0 0
E.coli 1 0 10 E.coli 1 0 MeropenemMeropenemMeropenem 42 0 1 0 0 1 1
2 2 E.coli 1 0 10 E.coli 1 0 MeropenemMeropenemMeropenem 14 0 0 0 0 0 1
2 1 No growth 10 E.coli 0 0 MeropenemErtapenem Ertapenem 15 0 0 0 0 0 0
2 1 No growth 1 E.coli 1 0 MeropenemMeropenemMeropenem 14 0 0 1 0 0 0
2 1 E.coli 1 0 10 E.coli 1 0 MeropenemMeropenemMeropenem 10 0 0 0 0 0 0
2 1 No growth 1 Enterococcus 0 0 MeropenemLinezolid Linezolid 14 0 0 1 0 1 1
2 1 E.coli 1 0 10 E.coli 1 0 MeropenemMeropenem / LinezolidMeropenem / Linezolid27 0 1 0 0 0 0
2 1 No growth 10 E.coli 0 0 MeropenemPiperacillin tazobactumPiper cillin tazobactum10 0 0 0 0 0 0
2 1 No growth 10 E.coli 1 0 MeropenemMeropenemMeropenem 24 1 0 0 0 1 1
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surgical bedcharge labinvest noninvas invastest drugs profcharge pertravel relative total dayfood relative1 totalfood dayaccom relative2 totalaccomlosspay losswages moneyarran
0 2775 12240 3475 0 20294 8790 60 2 2980 200 2 3200 0 0 0 0 0 1
0 27528 37332 9430 10305 32174 8200 150 2 1140 300 2 660 0 0 0 0 0 1
0 37370 52039 11445 0 62864 62864 80 2 1040 0 0 0 0 0 0 0 0 1
0 13910 10240 2405 0 17324 4550 150 2 1950 100 2 2600 0 0 0 0 0 2
0 50011 69850 1935 3185 11080 10250 120 2 240 100 2 3000 0 0 0 0 0 1
0 8800 7977 1655 0 18948 2800 420 2 700 100 2 2400 0 0 0 0 0 1
0 16050 13888 3070 0 19483 5250 250 2 3000 0 0 0 0 0 0 0 0 1
0 12210 15267 2560 0 9371 3850 700 2 2350 60 2 1320 0 0 0 0 0 2
0 21400 24300 9200 0 18922 7000 130 2 900 100 2 4000 0 0 0 0 0 2
0 26750 32450 8620 0 113954 8750 150 2 3300 250 2 7250 0 0 0 0 10000 1
0 30880 120829 12460 0 29204 28640 2500 2 6500 100 2 2400 0 0 0 0 0 1
0 87430 189327 12875 2980 207891 20685 650 2 2250 60 2 9200 0 0 0 0 0 2
0 8560 2621 780 0 19686 2800 70 1 1190 80 1 840 0 0 0 0 0 1
0 2140 7314 750 0 2873 10700 19 3 414 160 2 960 0 0 0 0 0 1
0 44032 63820 6950 0 2536 12950 200 3 5200 150 3 8160 0 0 0 0 0 2
0 16050 27827 8095 0 25326 5250 17 1 34 100 1 1500 0 0 0 900 1500 1
0 4280 6420 2030 0 35963 1400 540 2 980 195 2 1580 0 0 0 0 0 1
0 11070 14240 6655 0 47478 3850 320 3 960 276 2 3916 0 0 0 0 1320 2
0 4240 1661 750 0 4204 3350 40 2 280 100 2 300 0 0 0 0 0 2
0 8910 12483 2925 0 9098 5035 40 3 1580 60 3 2260 0 0 0 0 0 1
0 29694 46117 3275 0 48722 10935 20 2 820 60 2 90 0 0 0 0 0 2
0 6810 11618 1510 1570 23759 4350 280 2 1340 60 2 410 0 0 0 0 0 2
0 63540 69473 17840 5300 17493 15400 540 2 2600 60 2 900 0 0 0 0 0 2
0 8355 4825 1265 0 3987 4685 130 2 260 60 2 1660 0 0 0 0 0 1
0 97245 147259 3410 0 26830 24635 2080 2 6000 100 2 5000 0 0 0 0 0 2
0 19510 34824 1800 0 15368 6650 270 2 1050 100 2 3600 0 0 0 0 0 1
0 62840 80160 30140 0 16986 24210 250 2 1300 100 2 3600 0 0 0 0 0 1
0 13910 24264 5455 0 25326 4550 1200 2 2480 195 2 2641 0 0 0 0 0 1
0 14230 29186 5618 2080 7667 7725 20 2 720 60 2 2700 0 0 0 0 0 2
0 26807 38543 10505 0 37124 8885 20 3 1200 100 3 8000 0 0 0 0 0 2
0 5350 13515 1265 0 6749 1750 20 2 300 195 2 2215 0 0 0 0 0 1
0 10700 13286 1265 0 18090 3500 40 2 2400 100 2 2950 0 0 0 1200 0 1
0 4280 6444 1085 0 7161 1400 60 2 120 195 2 7980 0 0 0 0 0 1
0 15540 23650 1455 0 14322 5320 30 2 660 100 2 4200 0 0 0 0 1400 1
0 8560 18240 12880 0 8184 3200 40 1 240 200 1 200 0 0 0 130 130 2
0 9630 13420 1510 0 11752 3240 20 2 440 195 2 3555 0 0 0 1800 0 1
0 5350 6820 1455 0 7161 1750 200 2 1800 195 2 2475 0 0 0 0 0 1
0 11770 13700 9415 0 7616 3850 420 2 420 195 2 4785 0 0 0 0 0 1
0 16050 21240 7880 0 25326 5250 120 2 3600 195 2 4425 0 0 0 2700 0 1
0 7490 14255 4020 0 19038 2450 60 1 180 195 1 2065 0 0 0 0 0 1
0 5550 4020 2470 0 25326 1650 180 2 3400 195 2 1475 0 0 0 0 0 1
0 8560 6280 1455 0 8313 2800 100 2 420 100 2 2400 0 0 0 1120 0 2
0 6660 9620 8760 0 14452 2400 40 2 2480 195 2 2370 0 0 0 0 0 1
0 8560 10133 1880 0 8428 280 50 2 2500 195 2 3480 0 0 0 1600 0 2
0 8560 11621 5310 0 13266 2800 60 2 1040 195 2 3480 0 0 0 0 0 1
0 30240 43672 29862 0 40401 11200 200 4 4200 196 4 18928 0 0 0 0 5600 2
0 14430 23625 9525 0 43416 5200 50 2 830 195 1 3835 0 0 0 0 0 2
0 11770 12360 11490 7930 71872 4400 20 2 6900 195 2 4345 0 0 0 0 0 2
0 8560 23870 1985 0 17096 2800 20 1 40 195 1 2040 0 0 0 0 800 2
0 6610 11350 990 0 5670 1050 20 2 720 80 2 480 0 0 0 0 300 1
0 10700 21420 3225 0 17487 3500 20 2 650 195 2 3650 0 0 0 0 0 1
0 7490 11250 1250 0 12663 3850 15 3 610 50 3 1190 0 0 0 0 0 1
0 11700 16840 2560 0 12706 3850 40 2 1640 175 2 1925 0 0 0 0 0 1
0 7490 8218 1140 0 32753 2800 20 2 340 195 2 2765 0 0 0 700 700 2
0 5350 8230 1130 0 7267 4250 20 2 280 100 2 1500 0 0 0 0 0 1
0 12090 26800 17200 2980 12269 8800 20 2 560 60 2 1620 0 0 0 0 0 2
0 20330 11616 7220 6650 25284 15975 200 2 3600 195 2 7505 0 0 0 0 0 1
0 29960 32971 13080 4980 26598 9800 320 2 7480 195 2 11060 0 0 0 0 2800 2
0 19260 21040 2545 0 26120 6300 40 1 240 140 1 2520 0 0 0 100 100 2
0 8910 10777 1570 0 3489 3700 20 2 380 60 2 1940 0 0 0 0 0 1
0 5300 2376 2015 0 7555 3700 60 4 1740 100 4 2400 0 0 0 0 0 1
0 7920 3193 3025 0 3482 8460 20 2 90 0 0 0 0 0 0 0 0 1
0 5750 12146 750 2080 22663 3950 20 2 440 60 2 480 0 0 0 0 0 1
0 15980 18472 1915 1040 22862 8800 20 2 556 60 2 2520 0 0 0 0 0 2
1 35748 52925 5320 0 25312 10495 40 2 1600 100 2 300 0 0 0 0 0 2
0 12320 267 5120 0 4013 6150 20 2 760 195 2 8190 0 0 0 0 0 1
0 5300 14025 2610 2080 10394 3950 20 2 240 100 2 1500 0 0 0 0 0 1
0 13150 10383 750 0 13859 8805 40 3 1700 100 3 3900 0 0 0 0 0 2
0 8560 18130 1265 0 19296 2800 200 2 3600 196 2 4704 0 0 0 1120 0 1
0 12840 16280 14485 11270 57553 4200 20 2 1440 195 2 4680 0 0 0 0 0 1
1 6360 3227 4990 1495 11384 4050 20 2 240 0 0 0 0 0 0 0 0 1
0 7490 11365 7205 0 16884 2450 120 2 2640 120 2 1680 0 0 0 560 0 2
0 6420 8348 4735 0 18203 2100 40 2 320 100 2 1200 0 0 0 720 720 2
0 3210 6168 6750 0 7236 1050 20 2 420 80 2 720 0 0 0 0 240 2
0 19980 42840 9530 6170 8428 7650 28 2 2628 60 2 5870 0 0 0 3240 0 2
0 58600 63240 21740 11240 75978 11550 6000 3 6000 135 3 13365 0 0 0 0 300 2
0 4560 4320 940 0 13338 1400 80 1 520 100 1 800 0 0 0 0 0 2
0 4280 8170 5160 0 9413 1400 120 2 2960 195 2 1585 0 0 0 0 0 1
0 7490 11240 6710 0 24552 2800 100 2 1800 195 2 2485 0 0 0 1120 0 1
0 7490 9620 1240 0 6321 2520 40 2 960 100 2 2100 0 0 0 840 0 2
0 18190 26280 8335 6060 42966 8150 20 1 840 100 1 2400 0 0 0 0 0 1
0 16050 24174 1987 0 25242 5250 60 2 1200 120 2 3600 0 0 0 1500 0 2
0 18190 31240 2735 0 18489 6800 20 1 540 195 1 5015 0 0 0 0 0 1
0 143260 162820 18240 4620 92430 84200 40 2 2780 195 2 9735 0 0 0 0 3300 2
0 11770 23440 2665 0 17640 4400 40 4 1600 20 5 50 0 0 0 0 600 2
0 6420 9620 1880 0 38180 2100 60 3 180 195 3 2910 0 0 0 0 0 2
0 15540 16424 7260 11775 5146 4800 50 2 1400 200 2 5600 0 0 0 0 0 1
0 8560 14420 2070 0 18090 2800 50 2 350 195 2 2840 0 0 0 0 0 1
0 21400 26280 7460 12685 8790 7000 500 3 7500 195 3 7370 0 0 0 0 0 1
0 28890 22563 9165 0 20954 9450 100 1 1580 60 1 540 0 0 0 840 0 2
0 5350 12898 10465 0 10700 1750 26 2 680 60 2 600 0 0 0 0 0 2
0 11770 13300 7735 4980 50652 3610 300 1 6100 80 1 880 0 0 0 0 0 1
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education marital ill wrnghealthquality satihealth phypain medtreat enjoylife meaningfulconcent safelife environ everyday appearancemoney daytoday leisure getaround
2 3 1 Pyelonephritis 2 2 2 2 3 3 3 2 2 2 2 2 2 2 2
1 3 1 Pyelonephritis 4 2 5 4 2 2 2 3 2 2 2 2 2 2 2
1 3 1 Pyelonephritis 2 2 3 4 2 2 2 2 3 2 2 2 2 2 2
3 6 1 Pyelonephritis 2 2 4 4 2 2 2 2 2 2 2 2 2 2 2
3 3 1 Pyelonephritis 2 2 4 4 2 2 2 2 2 2 2 2 2 2 2
1 6 1 Pyelonephritis 3 3 4 3 2 2 2 2 2 3 3 4 4 4 4
2 2 1 Pyelonephritis 2 2 4 4 2 2 3 3 3 2 3 2 2 2 2
2 3 1 Pyelonephritis 2 2 4 4 2 2 2 2 2 2 2 2 3 2 2
2 6 1 Pyelonephritis 2 2 4 4 2 3 2 3 3 3 2 2 3 3 2
2 2 1 Pyelonephritis 2 3 3 3 3 3 3 3 3 2 3 3 3 3 3
3 2 1 Pyelonephritis 2 2 4 4 2 2 2 2 2 2 2 2 2 2 2
2 2 1 Pyelonephritis 2 2 4 4 2 2 2 2 2 2 2 2 2 2 2
3 1 1 Pyelonephritis 3 3 3 4 2 3 3 3 3 4 4 4 3 3 3
2 2 1 pyelonephritis 2 2 4 4 2 2 2 3 3 3 3 3 3 3 2
2 2 1 pyelonephritis 2 2 4 4 2 2 2 2 2 2 2 2 2 3 2
2 2 1 pyelonephritis 2 2 4 4 2 2 2 2 2 2 2 2 2 2 2
4 3 1 Pyelonephritis 4 3 3 3 3 2 2 2 2 3 3 3 2 3 3
2 3 1 Pyelonephritis 2 2 4 4 3 2 2 2 2 3 2 2 2 2 2
3 3 1 Pyelonephritis 3 3 4 4 4 3 3 2 2 3 2 2 2 2 3
4 3 1 Pyelonephritis 3 2 4 3 4 2 2 2 2 3 3 2 3 2 3
2 3 1 Pyelonephritis 2 2 4 4 3 3 3 3 3 2 2 2 3 3 2
2 3 1 Pyelonephritis 2 2 4 3 3 4 3 3 3 2 2 2 2 2 3
4 3 1 Pyelonephritis 2 2 3 4 2 2 2 2 2 3 2 2 2 2 1
4 1 1 Pyelonephritis 2 2 4 4 2 3 3 3 3 2 3 3 2 2 2
3 3 1 Pyelonephritis 3 3 4 3 3 4 3 3 3 3 3 3 2 2 2
4 3 1 Pyelonephritis 1 1 2 2 1 2 1 1 2 1 1 1 1 2 1
4 3 1 Pyelonephritis 2 3 3 4 2 2 2 2 2 2 3 3 2 3 3
2 3 1 Pyelonephritis 3 3 4 3 3 3 2 3 3 2 3 3 3 3 3
2 3 1 Pyelonephritis 2 2 4 4 2 3 2 3 3 2 2 1 2 2 3
3 3 1 Pyelonephritis 3 3 5 4 2 2 2 3 3 3 3 3 3 3 2
4 3 1 Pyelonephritis 2 2 4 3 2 2 2 3 2 2 2 3 3 3 2
2 3 1 Pyelonephritis 2 3 4 4 2 2 3 3 3 1 2 1 2 2 2
2 3 1 Pyelonephritis 3 2 4 3 3 2 2 3 3 2 3 3 2 2 2
2 3 1 Pyelonephritis 2 2 4 3 3 2 2 2 2 2 2 1 2 2 2
2 3 1 Pyelonephritis 2 3 3 3 3 3 2 2 2 3 3 1 3 2 2
2 3 1 Pyelonephritis 4 4 4 4 2 2 2 2 3 4 4 2 2 2 4
4 1 1 Pyelonephritis 3 2 4 4 3 5 5 5 5 3 3 5 4 4 2
4 1 1 Pyelonephritis 4 2 4 4 2 2 4 4 4 4 4 3 3 3 4
4 3 1 Pyelonephritis 4 2 4 4 3 3 3 3 3 3 3 3 2 2 3
3 3 1 Pyelonephritis 3 2 4 4 2 2 2 2 2 2 2 2 2 2 2
4 3 1 Pyelonephritis 2 3 3 3 2 2 2 2 2 3 3 4 2 2 2
2 3 1 Pyelonephritis 2 2 4 4 2 2 2 2 3 3 2 1 2 2 2
2 3 1 Pyelonephritis 2 3 4 3 3 3 2 2 2 3 2 2 2 3 2
3 3 1 Pyelonephritis 3 3 4 4 2 3 2 2 2 3 3 2 4 3 4
3 3 1 Pyelonephritis 2 2 4 3 3 2 2 2 2 3 2 1 3 2 2
4 3 1 Pyelonephritis 2 2 3 3 3 3 3 4 4 3 3 4 4 4 2
4 3 1 Pyelonephritis 2 3 3 4 3 2 2 3 3 2 3 3 3 3 3
3 3 1 Pyelonephritis 4 2 2 2 3 2 2 2 3 4 4 3 2 2 2
2 1 1 Pyelonephritis 4 4 4 4 3 2 2 2 2 1 1 1 2 2 1
2 3 1 Pyelonephritis 3 2 3 3 3 2 4 4 3 3 3 2 2 2 4
4 3 1 Pyelonephritis 2 2 4 3 2 3 3 3 3 3 3 3 2 2 2
1 3 1 Pyelonephritis 2 3 3 3 3 2 2 3 3 1 2 3 2 2 1
2 3 1 Pyelonephritis 4 2 3 4 2 3 2 3 2 2 2 5 4 4 4
2 3 1 Pyelonephritis 2 2 4 3 2 2 3 2 2 3 2 3 2 2 2
2 3 1 Pyelonephritis 2 2 4 4 2 2 2 2 2 3 3 2 2 2 3
2 3 1 Pyelonephritis 2 2 4 3 2 2 2 2 2 3 2 2 2 2 3
4 3 1 Pyelonephritis 4 2 3 4 3 4 3 5 4 2 2 2 4 4 4
2 3 1 Pyelonephritis 2 2 4 4 2 3 2 2 2 2 3 2 2 2 2
1 6 1 Pyelonephritis 2 2 4 4 2 2 2 2 2 2 2 2 2 2 2
4 1 1 Pyelonephritis 2 2 4 2 2 2 2 2 3 4 3 2 2 2 4
3 3 1 Pyelonephritis 2 2 3 3 3 2 3 3 3 3 2 3 3 3 2
4 1 1 Pyelonephritis 4 2 4 4 2 2 4 4 4 4 3 4 3 2 2
2 3 1 Pyelonephritis 2 2 3 4 2 2 2 2 2 2 2 2 3 2 2
2 3 1 Pyelonephritis 2 2 3 4 2 2 3 3 3 2 2 2 3 3 2
3 3 1 Pyelonephritis 3 3 4 4 2 2 2 2 2 2 2 2 3 2 3
2 3 1 Pyelonephritis 2 2 4 4 2 2 2 2 2 2 2 2 2 2 2
3 3 1 Pyelonephritis 2 3 4 4 4 4 4 4 4 2 2 3 4 4 4
3 1 1 Pyelonephritis 2 2 4 4 2 2 2 2 2 2 2 2 3 2 2
2 3 1 Pyelonephritis 3 2 3 4 2 4 3 3 3 3 3 2 2 2 2
3 3 1 Pyelonephritis 2 3 4 4 1 1 2 2 2 2 2 2 2 2 2
2 3 1 Pyelonephritis 2 2 4 4 2 2 2 2 2 3 2 2 3 3 3
3 3 1 Pyelonephritis 2 3 4 4 2 2 2 2 2 2 2 2 3 2 2
2 3 1 Pyelonephritis 3 3 4 5 1 2 3 3 3 4 4 4 3 3 4
2 6 1 Pyelonephritis 2 2 4 4 2 1 2 2 2 1 2 2 2 2 2
2 3 1 Pyelonephritis 2 2 2 4 2 2 2 2 2 3 3 2 2 2 2
4 3 1 Pyelonephritis 2 2 4 4 2 2 2 2 2 2 2 2 2 2 2
2 3 1 Pyelonephritis 2 2 4 4 2 2 2 2 3 2 2 2 2 2 2
4 3 1 Pyelonephritis 2 2 3 4 2 4 4 4 4 3 3 3 3 3 3
2 3 1 Pyelonephritis 2 2 4 4 2 2 2 2 2 2 2 2 2 2 2
4 3 1 Pyelonephritis 2 2 4 4 2 3 2 3 2 3 2 2 2 2 2
3 3 1 Pyelonephritis 2 2 4 3 2 2 2 2 2 2 2 2 2 2 2
3 3 1 Pyelonephritis 2 2 4 4 2 3 2 2 2 3 2 2 2 2 2
2 3 1 Pyelonephritis 4 3 3 2 3 3 3 3 3 4 3 3 2 3 3
3 3 1 Pyelonephritis 2 2 4 4 2 2 2 2 2 2 2 2 2 2 2
3 3 1 Pyelonephritis 2 2 4 4 2 2 2 2 2 2 2 2 2 2 3
4 1 1 Pyelonephritis 2 2 4 4 2 2 2 2 2 2 2 2 2 2 3
2 3 1 Pyelonephritis 2 4 4 4 2 2 2 3 3 2 2 4 3 3 3
2 3 1 Pyelonephritis 2 2 4 4 2 2 2 3 2 2 2 2 2 2 3
1 6 1 Pyelonephritis 2 2 4 4 2 3 2 4 4 2 3 3 2 2 2
3 3 1 Pyelonephritis 1 1 5 5 1 1 1 2 2 1 1 1 3 2 1
2 3 1 Pyelonephritis 1 1 1 1 1 1 1 2 2 1 2 4 4 1 1
2 6 1 Pyelonephritis 2 2 4 4 2 2 2 2 2 2 2 2 2 2 2
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sleep ability capacity yourself personal sexlife friends liveplace healthser transport negfeel help domain1 domain2 domain3 domain4 scaled1 scaled2 scaled3 scaled4
2 2 2 2 2 3 3 3 3 3 4 1 14 17 8 19 25 45.83 41.67 34.38
2 2 2 3 3 3 4 4 4 4 2 1 19 13 10 23 42.86 29.17 58.33 46.88
2 2 2 3 2 3 2 2 2 3 3 1 17 14 7 18 35.71 33.33 33.33 31.25
2 2 2 3 3 3 3 2 2 2 2 1 18 13 9 16 39.29 29.17 50 25
2 2 2 2 2 3 4 4 4 3 2 1 18 12 9 21 39.29 25 50 40.63
4 4 4 4 4 3 4 4 4 4 2 1 26 15 11 28 67.86 37.5 66.67 62.5
2 2 2 2 2 3 2 2 2 2 3 1 18 15 7 18 39.29 37.5 33.33 31.25
2 2 2 2 2 3 2 2 2 2 2 1 18 12 7 17 39.29 25 33.33 28.13
3 2 2 2 2 3 4 3 4 4 2 1 20 13 9 25 46.43 29.17 50 53.13
3 3 3 3 3 3 3 3 3 3 3 1 20 18 9 24 46.43 50 50 50
2 2 2 1 2 3 4 4 4 4 3 1 18 12 9 22 39.29 25 50 43.75
1 2 2 2 2 3 4 3 3 3 3 1 17 13 9 19 35.71 29.17 50 34.38
3 3 3 4 4 4 4 4 4 4 4 1 23 20 12 28 57.14 58.33 75 62.5
4 4 4 4 4 3 4 4 4 4 4 1 25 17 11 27 64.29 45.83 66.67 59.38
2 2 2 2 4 3 4 3 3 3 3 1 18 13 11 20 39.29 29.17 66.67 37.5
2 2 2 2 2 3 2 2 3 3 2 1 18 12 7 18 39.29 25 33.33 31.25
4 4 4 4 4 3 4 4 4 4 5 1 24 19 11 24 60.71 54.17 66.67 50
2 2 2 2 2 2 2 3 2 2 4 1 19 15 6 17 42.86 37.5 25 28.13
2 2 2 2 2 3 2 3 3 3 4 1 20 18 7 19 46.43 50 33.33 34.38
3 4 3 3 4 3 4 4 4 3 4 1 23 18 11 22 57.14 50 66.67 43.75
4 4 3 4 4 3 4 4 2 2 4 1 23 19 11 22 57.14 54.17 66.67 43.75
2 3 3 4 4 3 4 4 4 4 4 1 20 20 11 24 46.43 58.33 66.67 50
2 1 1 3 3 3 4 4 4 3 5 1 15 16 10 21 28.57 41.67 58.33 40.63
3 3 3 3 3 3 3 3 3 3 2 1 21 16 9 22 50 41.67 50 43.75
2 3 3 2 3 3 3 3 3 3 2 1 20 17 9 22 46.43 45.83 50 43.75
1 1 1 1 1 3 2 2 3 3 2 1 9 8 6 15 7.14 8.33 25 21.88
2 3 3 4 2 3 2 2 3 3 3 1 20 16 7 20 46.43 41.67 33.33 37.5
3 3 3 2 3 3 4 4 3 3 4 1 21 17 10 25 50 45.83 58.33 53.13
2 3 3 2 2 3 3 3 4 3 4 1 21 15 8 21 50 37.5 41.67 40.63
3 3 3 2 2 3 2 2 2 3 5 1 23 16 7 22 57.14 41.67 33.33 43.75
2 3 2 2 3 3 3 2 2 3 5 1 18 15 9 21 39.29 37.5 50 40.63
2 2 2 3 3 3 3 2 3 3 4 1 17 16 9 19 35.71 41.67 50 34.38
2 2 2 2 2 3 3 2 3 3 4 1 17 16 8 21 35.71 41.67 41.67 40.63
2 2 2 2 2 3 2 2 3 2 3 1 17 14 7 16 35.71 33.33 33.33 25
2 2 2 2 2 3 4 4 4 3 4 1 17 17 9 21 35.71 45.83 50 40.63
4 4 3 4 3 3 4 4 4 3 4 1 27 18 10 22 71.43 50 58.33 43.75
4 4 4 4 4 3 4 4 4 4 5 1 25 25 11 35 64.29 79.17 66.67 84.38
4 4 4 4 4 3 4 4 4 3 5 1 28 21 11 28 75 62.5 66.67 62.5
2 2 2 2 3 3 2 2 2 2 4 1 20 18 8 19 46.43 50 41.67 34.38
2 2 2 2 2 3 2 2 3 3 2 1 18 12 7 18 39.29 25 33.33 31.25
2 3 3 2 3 3 4 4 4 4 2 1 19 13 10 24 42.86 29.17 58.33 50
2 2 2 3 3 3 3 3 3 3 3 1 19 14 9 19 42.86 33.33 50 34.38
3 3 3 3 3 3 3 3 3 2 4 1 21 17 9 19 50 45.83 50 34.38
2 4 4 3 3 3 4 4 3 3 4 1 25 17 10 23 64.29 45.83 58.33 46.88
2 2 2 2 2 3 2 2 2 3 2 1 18 13 7 17 39.29 29.17 33.33 28.13
2 2 2 2 2 3 4 4 4 4 4 0 17 18 9 32 35.71 50 50 75
4 4 4 4 4 3 4 3 3 3 3 0 24 17 11 24 60.71 45.83 66.67 50
2 2 2 2 2 3 2 2 2 3 4 1 16 17 7 19 32.14 45.83 33.33 34.38
2 1 1 1 4 3 4 4 4 3 3 1 14 12 11 20 25 25 66.67 37.5
4 4 4 4 4 3 4 4 3 3 4 1 25 20 11 23 64.29 58.33 66.67 46.88
4 4 4 3 3 3 4 4 4 3 3 1 24 17 10 24 60.71 45.83 58.33 50
4 3 2 3 4 3 4 4 4 4 4 1 17 16 11 25 35.71 41.67 66.67 53.13
4 4 3 4 4 3 3 4 5 5 4 1 24 17 10 32 60.71 45.83 58.33 75
2 3 2 2 2 3 3 3 3 3 4 1 19 15 8 20 42.86 37.5 41.67 37.5
1 2 2 2 3 3 4 3 3 3 4 1 19 15 10 19 42.86 37.5 58.33 34.38
2 2 2 3 2 3 2 3 2 2 4 1 19 15 7 17 42.86 37.5 33.33 28.13
2 2 2 4 4 3 4 4 4 4 5 1 19 21 11 31 42.86 62.5 66.67 71.88
2 2 2 2 2 3 3 2 2 2 4 1 18 16 8 16 39.29 41.67 41.67 25
2 2 2 2 2 3 2 2 2 2 2 1 18 12 7 16 39.29 25 33.33 25
4 4 2 4 3 3 4 4 3 2 4 1 24 17 10 20 60.71 45.83 58.33 37.5
2 3 3 3 3 3 4 3 3 3 3 1 19 16 10 24 42.86 41.67 58.33 50
3 2 2 2 2 3 4 4 4 3 4 1 21 17 9 28 50 45.83 50 62.5
2 2 2 2 2 3 2 2 3 3 3 1 17 13 7 19 35.71 29.17 33.33 34.38
2 2 2 3 3 3 4 2 2 4 2 1 17 14 10 22 35.71 33.33 58.33 43.75
2 3 3 3 2 3 3 3 3 3 3 1 21 14 8 20 50 33.33 41.67 37.5
2 2 3 2 2 2 2 2 2 2 4 1 19 14 6 16 42.86 33.33 25 25
2 2 4 2 4 3 4 4 4 4 4 1 22 20 11 31 53.57 58.33 66.67 71.88
2 2 2 2 2 3 2 2 2 2 4 1 18 14 7 17 39.29 33.33 33.33 28.13
3 3 3 3 3 3 4 3 3 2 5 1 21 20 10 20 50 58.33 58.33 37.5
2 2 2 2 3 3 3 3 3 3 3 1 18 11 9 19 39.29 20.83 50 34.38
2 2 2 3 3 3 2 3 3 3 4 1 20 15 8 21 46.43 37.5 41.67 40.63
2 2 2 2 2 3 2 2 2 3 4 1 18 14 7 18 39.29 33.33 33.33 31.25
4 3 3 4 4 3 3 4 4 4 5 1 27 19 10 28 71.43 54.17 58.33 62.5
2 2 2 2 2 3 4 4 2 2 4 1 17 13 9 18 35.71 29.17 50 31.25
2 2 2 2 2 3 4 2 2 3 3 1 17 14 9 17 35.71 33.33 50 28.13
2 2 2 2 2 3 4 4 4 4 3 1 18 13 9 22 39.29 29.17 50 43.75
2 2 2 2 2 3 2 2 2 2 4 1 18 14 7 17 39.29 33.33 33.33 28.13
3 3 4 3 3 3 4 3 3 3 4 1 23 20 10 26 57.14 58.33 58.33 56.25
3 2 2 3 2 3 2 2 2 2 3 1 19 14 7 16 42.86 33.33 33.33 25
2 2 2 2 2 2 2 2 2 2 4 1 19 15 6 17 42.86 37.5 25 28.13
2 2 2 2 2 2 2 2 2 2 4 1 17 14 6 16 35.71 33.33 25 25
1 2 2 3 2 3 3 2 3 2 4 1 18 16 8 17 39.29 41.67 41.67 28.13
3 3 3 3 3 3 4 4 4 4 5 1 21 20 10 26 50 58.33 58.33 56.25
2 2 2 2 2 3 2 2 2 2 4 1 18 14 7 16 39.29 33.33 33.33 25
3 3 3 3 3 3 3 3 3 3 3 1 22 14 9 19 53.57 33.33 50 34.38
5 5 5 5 4 3 5 5 5 5 5 1 28 18 12 25 75 50 75 53.13
2 2 2 2 2 3 4 4 4 5 4 1 19 14 9 29 42.86 33.33 50 65.63
2 2 3 3 3 3 4 4 3 4 4 1 20 15 10 22 46.43 37.5 58.33 43.75
2 3 2 3 4 3 4 4 4 4 4 1 19 17 11 27 42.86 45.83 66.67 59.38
4 2 2 2 3 3 4 4 4 3 3 1 20 9 10 21 46.43 12.5 58.33 40.63
2 2 1 1 3 1 4 4 5 4 2 1 9 8 8 26 7.14 8.33 41.67 56.25
2 3 3 2 3 3 4 4 4 4 4 1 20 14 10 22 46.43 33.33 58.33 43.75
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